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Long-term and recent use of combined oral contraceptives (COCs) was suggested to be a 
risk factor of cervical cancer. It is unclear whether the association is driven by COC’s 
effect(s) on carcinogenesis and/or on upstream events of HPV infection, as study findings 
on the association between hormonal contraceptive use and HPV infection have been 
inconsistent. Understanding the effect of hormonal contraceptive use on HPV detection 
and cervical immune milieu in women older than 35 years may provide insight into the 
biological mechanisms underlying the impact of hormonal contraceptive use on cervical 
cancer risk.   
Objectives: 
A prospective cohort of pre- and perimenopausal females (age range: 35-54) who had 
normal cervical cytology were followed to investigate the association between cervical 
HPV detection and hormonal contraceptive use (n=530). The study has 3 aims:  Aim 1:  
To determine the association of hormonal contraceptive use with HPV prevalence at 
baseline. Aim 2: To compare the odds of new HPV DNA detection between users and 
non-users of hormonal contraceptives. Aim 3: To describe and compare differences in the 
host cervical cytokine profiles between hormonal contraceptive users and non-users who 
were HPV-negative at baseline.  
Methods: 
Pre- and perimenopausal women (age range: 35-54 years) were recruited from 




contraceptive use, HPV genotypes, history of other sexually transmitted infections, Pap 
smear diagnoses, sexual behavioral and reproductive characteristics. For Aim 1:  
associations were assessed using prevalence ratios (PRs) with 95% confidence intervals 
(CIs). For Aim 2: associations between hormonal contraceptive use and incident HPV 
detection were measured by odds ratios (ORs) with 95% confidence intervals (CIs) 
estimated in generalized estimating equation models. For Aim 3: baseline pairs of 
cervical secretion samples matched in 5-year age groups were collected from current 
and non-current hormonal contraceptive users who were HPV-negative. Extracted 
specimens from cervical secretion samples were tested for 27 cytokines, chemokines and 
growth factors. Comparison of individual mean cytokine levels were made between user 
groups of hormonal contraceptives. Profile comparison was done using Spearman’s rank 
correlation to determine correlations for all pairwise combinations of the cytokines, 
chemokines, and growth factors measured in different strata of hormonal contraceptive 
use and type.  
Results: 
For Aim 1: more than 5 years’ use of progestin-only contraceptives (POCs) was 
associated with 3-fold increased prevalence of any HPV [adjusted prevalence ratio (aPR): 
3.16 (95% CI: 1.82-5.48)] and high-risk (HR)-HPV [aPR: 4.26 (95% CI: 1.60-11.30)] as 
compared to never POC users. Current POC use was positively associated with 
prevalence of HR-HPV (aPR: 2.44 (0.99-5.99) and any HPV (aPR: 1.58 (0.94-2.65) with 
the estimates bordering on statistical significance. For Aim 2: Relative to never POC 
users, increased incident detection of HR-HPV was observed among current users of 




behavioral factors. No similar associations were observed with the duration or recency of 
overall hormonal contraceptive or oral contraceptive (OC) use. For Aim 3: Compared to 
current users of hormonal contraceptives,  significantly more positive correlations were 
detected among proinflammatory cytokines as well as between proinflammatory and 
immunoregulatory cytokines in current hormonal contraceptive users. Compared to COC 
users, correlation coefficients were significantly lower in magnitude among 
immunoregulatory cytokines such as IL-9, IL-15 and IL-17, as well as IL-5, IL-15, IL-17 
in current POC users. Relative to non-current hormonal contraceptive users, current POC 
users were also found to have statistically significantly lower levels of IP10 and several 
immunoregulatory cytokines, including IL-12, IL-13, IL-15.  
Conclusions:  
Long-term and current use of POCs may be associated with increased risk of prevalent 
and incident HPV infection independent of sexual behavior among older women with 
normal cervical cytology. Our laboratory study showed differences in cytokine profiles 
between current and non-current hormonal contraceptive users as well as between current 
POC and COC users in HPV-negative women. These findings suggest differential 
impacts of exogenous hormones on cervical cytokine milieu, which in turn may 
potentially affect host responses to local genital infections. 
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Overview of the Dissertation  
 
by 







This thesis examined the association of hormonal contraceptive use with cervical 
human papillomavirus (HPV) detection among pre- and perimenopausal women in the 
U.S.  Data were obtained from an observational prospective study, HPV in 
perimenopause (HIP), conducted at gynecological clinics associated with the Johns 
Hopkins Medical Institutions in Baltimore, Maryland. 
 
The natural history of HPV during the menopausal transition is poorly understood (1-3). 
After the age of sexual debut, a second prevalence increase is observed around the age of 
menopause in several populations (1-3). This prevalence increase has been postulated to 
relate to changes in sexual behavior, age-related decreased immune responses and/or 
menopause-related endogenous hormonal changes (1, 4-6). Disruption of female sex 
hormonal profiles have been suggested to suppress immune responses to HPV and 
influence cervical cytokine profiles in vitro (7-15). While the influence of hormonal 
contraceptive use on HPV infection and cervical cancer has been evaluated previously 
among young women (16-35), its effect remains largely unclear among older women. A 
more intensive investigation of hormonal contraceptive use on HPV detection is therefore 
warranted in women approaching or going through menopause.  
 
This chapter serves as an introduction to the specific aims, brief methodologies, as well 
as public health significance of the studies undertaken in this dissertation. Chapter 2 gives 




knowledge on the role of hormonal contraceptive use in HPV infection and progression.  
Chapter 3 provides a manuscript on the association between hormonal contraceptive use 
and the prevalence of HPV detection in pre- and perimenopausal women. Chapter 4 
addresses the association of hormonal contraceptive use with new detection of HPV 
among pre- and perimenopausal women who had normal cervical cytology. Chapter 5 is a 
manuscript comparing the host cervical cytokine profiles between current and non-
current hormonal contraceptive users among HPV-negative women who were aged over 
35 years. Chapter 6 summarizes our study findings and discusses the strengths, 
limitations, public health implications of this dissertation research and future research 
directions. 
 
SPECIFIC AIMS  
The following specific aims were addressed in this thesis: 
 
Aim 1: To determine the association of hormonal contraceptive use with the 
prevalence of cervical HPV DNA detection  
A cross-sectional study was performed using baseline data collected on the recency and 
duration of overall hormonal contraceptive use, oral contraceptive use, and progestin-
only contraceptive use. Days of menstrual cycle, social demographic factors, sexual 
behavioral factors, reproductive history and smoking status were evaluated as potential 
confounders for HPV detection. Prevalence ratios with 95% confidence intervals were 





Aim 2: To estimate the association between hormonal contraceptive use and 
incident cervical HPV DNA detection 
Associations were evaluated with unadjusted and adjusted odds ratios with 95% 
confidence intervals using generalized estimating equation models. Primary exposures of 
interest included the recency and duration of overall hormonal contraceptive use, 
progestin-only contraceptive use and oral contraceptive use. 
 
Aim 3: To describe and compare differences in the host cervical cytokine profiles 
between current hormonal contraceptive users and non-current users 
A baseline cross-sectional study was performed using pairs of cervical secretion samples 
collected from current hormonal contraceptive users and non-current users who were 
matched in 5-year age groups. Subjects included were HPV-negative at baseline. 
Comparison of 27 individual mean cytokine, chemokine and growth factor levels was 
made between user groups of hormonal contraceptives. Profile comparison was done 
using Spearman’s rank correlation coefficients to determine correlations for all pairwise 
combinations of cytokines, chemokines, and growth factors measured in different strata 
of hormonal contraceptive use and type. 
 
PUBLIC HEALTH SIGNIFICANCE 
This research was motivated by the need to better understand how hormonal 
contraceptive use may impact HPV detection among older women, which is relevant to 





HPV DNA testing is anticipated to have increasing utility in early detection of cervical 
precancerous lesions in women, particularly in the post-vaccine era when cervical disease 
will become rarer and may escape cytology-based detection (36-42). Primary HPV DNA 
testing with cytology triage has been shown to be more sensitive than conventional 
morphology-based screening such as Pap smear (37-41), and more specific than 





Counseling for HPV-positive, cytology-negative women and optimization of screening 
intensity among older women can be challenging (41), because current knowledge is 
limited on (i) the risk factors for prevalent and persistent HPV detection in older women, 
(ii) whether the impacts of these risk factors are transient or long-term; and (iii) how 
these risk factors may predict the risk of progression to high-grade cervical lesions.  
 
Data from this dissertation research provide improved understanding of the association 
between hormonal contraceptive use and HPV detection in older women. The findings 
will contribute to generation of hypotheses and future studies to better define natural 
history of HPV infection among older females, which ultimately may benefit future 
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OVERVIEW: HPV AND CERVICAL CANCER 
 
Disease burden of cervical cancer 
In the U.S., cervical cancer is the third most common gynecologic cancer in women (1). 
The overall incidence of cervical cancer is 7.5 cases per 100,000 women in the U.S. (2). 
Worldwide, cervical cancer is the fourth most common cancer in women, with an 
estimated 528,000 new cases and 275, 000 deaths in year 2012 (3). Incidence of cervical 
cancer peaks at around age 65 years in the U.S. among women with an intact uterus (2). 
Cervical cancer accounts for 7.5% of all female cancer deaths globally (3). The majority 
(> 80%) of the global burden occurs in the less developed regions such as in Africa, 
South Asia, Central and Soutern America where proper routine screening is limited or 
lacking. Rates are lowest in Australia/New Zealand and Western Asia (3).  
 
HPV infection 
HPV infection is the most common viral sexually-transmitted infection in the world with 
a lifetime cumulative risk of >80% (2). Persistent infection of high-risk human 
papillomavirus (HPV) genotypes is a necessary but not sufficient cause of cervical cancer 
(4, 5). HPV is reported to be detected in 99.7 percent of cervical cancers (6), including 
almost all the histologic types such as squamous cell carcinoma (69% of cervical cancers), 
adenocarcinoma (25% of cervical cancers) and adenosquamous carcinoma (7).In many 
developed countries, the incidence of squamous cell carcinoma of the cervix has been 
observed to decrease while that of adenocarcinoma of the cervix is show to be on the rise 





NATURAL HISTORY AND EPIDEMIOLOGY OF HPV INFECTION  
 
The virus 
HPV belongs to the Papillomavirus genus of Papillomaviridae family. It infects only 
humans. Currently over 130 HPV genotypes have been identified, with ~ 40 genotypes 
causing mucosal infections based on tissue tropism (10, 11). The viruses are highly 
epitheliotropic as productive infections occur only within stratified epithelia of skin, 
anogenital tract, and oral cavity (10).  
 
HPV is a 8kb, double-stranded DNA virus that has a non-enveloped icosahedral capsid. 
The HPV genome is circular and contains 8 open reading frames consisting of 6 early (E1, 
E2, E4, E5, E6, E7) and 2 late (L1, L2) genes. The E6, E7 genes constitute the primary 
oncogenes. The E6 proteins have been shown to inhibit the transcriptional activity of p53 
and the abrogation of p53-induced apoptosis, while the E7 proteins lead to the loss of 
tumor suppressor (p105Rb) control over E2F transcription factors, resulting in 
unscheduled DNA synthesis and cellular proliferation (10).  
 
HPV infections of the genital tract have been subclassified into those caused by low-risk 
HPV genotypes and those caused by high-risk HPV genotypes. At least 13 high-
risk/oncogenic HPV genotypes have been identified according to WHO:  HPV 
genotypes16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 (10). Other studies have 




45, 51, 52, 56, 58, 59, 66, 68, 73, and 82 (2, 12).  Common low-risk HPV genotypes 
involved in mostly benign clinical disease includes HPV types: 6 and 11 (most common), 
40, 42, 43, 44, 53, 54, 61, 72, 73, and 81. 
 
HPV life cycle in the female genital tract 
Genital HPV infection is transmitted via sexual contact. The viral life cycle is similar in 
the cervix, vagina and vulva. HPV is believed to access basal epithelial cells at sites of 
micro-abrasions or injury. Basal cells normally undergo cell division, and the daughter 
cells migrate from the basement membrane into the suprabasal compartment. Under 
normal conditions, these cells initiate terminal differentiation as they migrate to the 
superficial epithelial layers. When basal cells are infected by HPV, early HPV genes E1, 
E2, E4, E5, E6, and E7 are expressed, and viral DNA replicates from the circular viral 
genome which normally resides as a nuclear plasmid in the cells. The infected suprabasal 
cells fail to withdraw from the cell cycle and continue to support DNA synthesis. Late 
genes L1, L2, are expressed in these infected cells as they migrate into the upper 
epithelial layers, where progeny virions are formed in the nuclei. These viruses are then 
shed from the epithelium and can initiate new infection (10, 13).  
 
Most HPV infections spontaneously resolve without clinical disease within 8-12 months, 







Progression of HPV infection to pre-malignant and malignant lesions 
HPV infection has been implicated in benign and malignant lesions in the genital tract. 
Low-risk HPV types 6 and 11 are commonly found in benign warts (condylomata 
acuminata). Persistence of high risk HPV infection at 1-2 years after initial infection has 
been shown to be highly predictive of a lifetime risk of pre-invasive and invasive cervical 
neoplasia (15). The most common HPV types involved in cervical cancer are HPV types 
16 and 18 (10).  
 
Figure 2.1 (Figure 2.1) is a schematic diagram illustrating the progression of persistent 
high-risk HPV infection to pre-malignant and malignant cervical lesions. The major steps 
include persistence of HPV infection, progression to low-grade intraepithelial lesions 
(LSILs), high-grade intraepithelial lesions (HSILs), carcinoma in situ and eventually 
invasive cancer. LSILs reflect productive viral replication. Less than 15% of LSIL 
progresses to HSIL and about 10-30% of HSIL eventually progresses to invasive cancer 
if left untreated (16-18). The progression of these untreated lesions to microinvasive and 
invasive cancer is associated with two events: (i) Inhibition of the differentiation process 
which leads to a cellular state that cannot support the normal full viral life cycle, (ii) and 
often integration of the episomal HPV genome into the host chromosomes. The 
consequences are the loss or disruption of E2, and subsequent upregulation of E6 and E7 
oncogene expression, which confers a growth advantage to these cells with impaired 





Factors driving the viral integration are still not fully understood. Recent research 
suggested that the risk of developing cervical cancer is strongly linked to a particularly 
vulnerable cell population within squamocolumnar junction (SCJ) of the cervix that have 
unique morphology and gene-expression profile (19-21). Study showed that expression of 
junction-specific genes was shared between these SCJ cells and most CIN3 and invasive 
cancers (20). This expression profile did not appear to be induced by viral oncoproteins; 
was not regenerated after excision; nor was it detected at HPV-infected sites that did not 
harbor these SCJ cells such as the vagina or vulva (19-21). The findings suggested that 
these cells were specific to the cervix and gave rise to the malignant cervical lesions (19-
21). 
 
Estradiol has also been shown to stimulate the transcription of HPV type 16 E6 and E7 
oncogenes in cell lines with integrated HPV 16
 
(22, 23). Studies have also reported a 
synergistic mechanism between long-term estrogen exposure and HPV 16 oncogenes that 





Epidemiologic risk factors of cervical cancer and HPV infection are discussed in the next 
sections. 
 
Epidemiology of HPV infection: Overview 
Prevalence of HPV infection is known to peak in the first few years following sexual 




common (27, 28). In the U.S., the proportion of high-risk versus low-risk HPV types had 
remained fairly unchanged across different age groups according to the 2003-2006 
NHANES survey (29).  
 
A second increase in prevalence has been noted in meta-analyses conducted among older 
women (over the age of 35 years) in several populations in Africa, Central and Southern 
America (26, 30). The same trend was observed also in Northern America by de Sanjose 
et al but not by Bruni et al when more recent studies were included (26, 30).  The cause 
for this second peak in prevalence is not well understood. Several mechanisms have been 
proposed to explain the prevalence increase, including population-specific cohort effects, 
re-exposure through new sexual contacts, re-emergence of latent HPV infections at older 
age, or physiologic changes at the cervix with aging that increase the efficiency of HPV 
detectability by current sampling methods (25-26, 31-32).  
 
While mid-life changes in sexual behavior has been suggested to be a potential 
underlying mechanism, recent evidence suggests that it cannot be the sole cause. In a 
study examining the incident HPV infection among women aged 16-23 years, a nontrivial 
proportion of women (0-16%) exhibited infection reappearance across HPV types within 
3 years of non-detection. Given that over 80% women in that study reported no new sex 
partners within 6-month- as well as 12-month periods before the date of detection, the 
reappearance of HPV detection was mostly attributed to changes of HPV detectability in 
the cervical tract, which in turn might be influenced by factors other than sexual 




immunocompetence levels (33). Another study conducted among HIV-positive women 
with CD4 cell count <200 cells/mm
3
 found a high rate of incident HPV detection in those 
who were sexually inactive for at least 18 months (22%) , which was not substantially 
lower than that of women who were sexually active (34). These data reflect potential 
reactivation of latent HPV infection that can become detectable in the setting of 
immunosuppression. 
 
While sexual behavioral risk factors is believed to be the main driving factor of 
acquisition of new HPV infection, factors which predispose to HPV persistence and/or 
carcinogenesis are not completely known. Host factors such as immune suppression (e.g. 
HIV),  menopause, infection by other sexually transmitted infection such as chlamydia, 
and viral factors such as coinfection with other HPV types and high viral load have been 
noted to be associated with persistent HPV infection (4, 5, 13, 35). Environmental risk 
factors which have been found to be associated with persistent HPV infection include 
cigarette smoking, high parity, and oral contraceptive use (4, 5, 36).  
 
The rest of this section will focus on current findings on the association of hormonal 
contraceptive use with HPV infection and cervical cancer.  
 
Hormonal contraceptive use as a risk factor for HPV infection and cervical cancer 
 




There is a general consensus on the risk of long-term combined oral contraceptive (COC) 
use on invasive cervical cancer or high-grade cervical neoplasia (37-42). According to a 
pooled analysis performed by the International Collaboration of Epidemiological 
Studies of Cervical Cancer (IARC) that comprised over 1500 HPV-positive cervical 
cancer cases and 200 controls, relative to never users of COCs, 5 or more years of COC 
use is associated with a significant 2-fold increased risk of invasive cervical cancer after 
adjustment for other risk factors (37). The risk declines to that of never users after 
cessation of use for more than 10 years (37). Similar association was observed in a 
pooled analysis of additional case–control and cross-sectional studies (40, 41).  
 
It remains unclear whether the association between COC and cervical cancer is driven by 
COC’s effect(s) on carcinogenesis and/or on upstream events such as HPV acquisition 
and persistence. 
 
Long-term OC use has been suggested in studies to increase the risk of both prevalent 
and persistent HPV infections. For instance, a recent study done in women aged 20-37 
years in Thailand (n=1250) showed that, relative to never users, long-term and recent use 
of COC was associated with a statistically significant 1.9-fold increase in overall adjusted 
HPV baseline prevalence, and a statistically significant 36%-reduction in HPV clearance 






Conclusions, however, have been inconsistent across cohort studies. Current findings on 
the association between OC/COC use and HPV acquisition, persistence and prevalence 
are summarized in tables 2.1-2.2 (Tables 2.1-2.2). Although some studies demonstrated a 
positive association between OC use and HPV persistence (44, 45), negative or null 
associations were observed in other studies (46-52). A few studies reported that OC use 
was associated with increased HPV acquisition (53, 54), but the findings were not 
replicated in other studies (44, 47, 48, 55-60). Inconsistency of findings has also been 
seen across studies looking at the association between OC use and HPV prevalence. A 
recent systematic review and a pooled analysis noted that neither a strong positive or 
negative association could be concluded between OC use and HPV prevalence (61, 62). 
Mixed findings with positive association (31, 43, 63-68) or null association (58, 69-86) 
have been reported in other studies.  
 
Association between HPV infection and use of other hormonal contraceptives 
There have been relatively few reports made on the association between use of other 
hormonal contraceptives and HPV infection or cervical cancer. According to a pooled 
analysis performed by IARC, the relative risk of invasive cervical cancer is moderately 
raised at 1.2-fold in long-term users versus never-users of progestagen-only injectable 
contraceptives (37).   
 
How the use of progesterone derivatives may influence the natural history of HPV is not 
well defined as related data are limited. In a large cross-sectional study conducted among 




Norplant and current use of injectable contraceptives were respectively associated with 
2.4-fold increased odds (95% CI: 0.9-6.0) and 2.2-fold increased odds (95% CI: 1.4-3.6) 
of oncogenic HPV prevalence after adjusting for sexual behavior (87). Two other cross-
sectional studies performed in the U.S. also reported positive associations of HPV 
prevalence with DMPA (63, 74).   
 
A recent 1-year prospective cohort study conducted among women with low-grade or 
equivocal cytological abnormalities in the U.S. (n= 2408) showed a marginal1.2-fold 
increase in odds (95% CI: 1.0-1.3) of persistent HPV infection among current users 
versus never users of injectable hormonal contraceptives (49), suggesting that use of 
progesterone derivatives may potentially increase the risk of cervical cancer by 
promoting HPV persistence.  
 
Findings, however, are mixed across studies, as summarized in tables 2.3 and 2.4 (Tables 
2.3, 2.4). No association was observed between HPV prevalence and intrauterine-device 
in a pooled analysis including 10 case-control studies and 16 prevalence studies (88). 
Multiple other studies also showed no significant associations with HPV prevalence (43, 
69, 70, 75, 71, 86, 89), and with HPV incidence or persistence (44, 46, 49, 50, 54).  
 
Heterogeneity in reported associations between HPV infection and hormonal 
contraceptive use across epidemiologic studies 
Heterogeneity in study findings are likely related to differences in study populations, 




collection and analyses. Residual confounding of sexual exposure to HPV, which might 
exist to different extent in studies due to variations in designs and population 
characteristics, can also contribute to the heterogeneity of reported data.  
 
The inconsistencies may also be partly explained by the intrinsic limitation of most HPV 
natural history studies in defining a persistent infection and an incident infection. Testing 
intervals in studies were seen to range from 2 months to 7 years, with a median of around 
6 months (13). Since specific HPV status of study participants prior to study entry is 
often not available for assessment, the distinction between a persistent and transient 
infection is arbitrary as it depends on the sampling frequencies and the time points of 
sampling in relation to the natural history of infection.  Defining a true incident infection 
can also be challenging as an “incident” detection of HPV can represent a newly acquired 
HPV subtype, a  recurrent infection of an HPV subtype that has cleared before study 
entry, or a reactivation of a “latent” infection detected at prior time points in the study. 
This limitation will be further discussed in Chapter 6 (Figure 6.2).  
 
Moreover, published data on the association between hormonal contraceptive use and 
HPV infection have mostly been focused on the use of OCs among women below the age 
of 40 years, or across a broad age spectrum with relatively small proportion of the study 
population in the older age group (Tables 2.1-2.4).  
 
It is therefore difficult to draw definite conclusions on the independent role(s) of the 




data, particularly among women aged 40 years or above who have not been the focus in 
most published studies, and whose sexual behavioral profiles are different from those of 
younger women (90).  
 
HPV infection and host immune response 
HPV is known to evade immune detection without inducing proinflammatory response in 
the keratinocytes via a number of mechanisms. Viral replication stays intraepithelial with 
little or no release into the local milieu of proinflammatory cytokines. There is no viremic 
or blood-borne phase in its life cycle. Free virus particles are shed from the surface of 
squamous epithelia with poor access to blood or lymph nodes where immune responses 
are initiated. Expression of the HPV oncogenes E6 and E7 has been shown in vitro to 
suppress interferon response, resulting in downregulation of chemokines and decreased 
recruitment of Langerhan cells (10, 91). HPV 16 E6 and E7 proteins have also been 
observed to downregulate in vitro expression of toll-like receptor 9, which mediates 
innate immune responses against bacterial and viral pathogens (92).  
 
Nevertheless, a primary HPV-infection is usually cleared naturally in approximately 90% 
of cases (93). Both humoral and cell-mediated responses are elicited in the host against 
HPV infection. Antibody responses to HPV infection are type-specific. The host's 
humoral IgG immune response to HPV infection is usually weak and varied among 
women. More than 40% of women do not seroconvert or the antibodies wane over time, 
suggesting that antibodies elicited by natural infection may not provide complete 





Cell-mediated immune response has been implicated in the clearance of HPV infection 
(95, 96, 97), but its exact mechanisms have not be fully elucidated. Studies have 
evaluated immune markers in cervical secretions (98-103), tissue-based immune markers 
(104-108), immune responses in patient-derived peripheral blood mononuclear cells 
(PBMCs) (109-113), and circulating immune markers in plasma or serum (114-119) to 
characterize immune responses against HPV infection. Main findings of these selected 
studies are summarized in table 2.5 (Table 2.5).  
 
Findings of these immune marker measurements have been largely inconsistent. This can 
be partly explained by the lack of consistency in sample collection and cytokine 
measurement methods, as well as outcome definitions used for analyses. The 
discrepancies could also stem from differences in the study populations, e.g. young 
versus old women. Furthermore, many studies focused on only one or few cytokines or 
immune marker, making it challenging to explore the interactions of all immune players 
involved.  
 
FEMALE SEX HORMONES AND HOST IMMUNE RESPONSES  
 
Association between HPV detection and endogenous female sex hormonal profile 
Persistence of HPV infection was reported to associate with old age in postmenopausal 
women (35). Lymphoproliferative responses in women older than 45 years was found to 




immunologic control of HPV infection may result in impaired clearance of HPV as 
women age through menopause (119).  
 
Female sex hormones include estrogen and progesterone. In females, estrogen and 
progesterone fluctuates due to variation in concentrations of pituitary luteinizing hormone 
(LH) and follicle stimulating hormone (FSH) during menstrual cycle. During follicular 
phase of the menstrual cycle, increase in 17 beta-estradiol and decrease in progesterone 
plasma concentrations are seen, while high plasma 17 beta-estradiol and progesterone 
concentrations occur in the luteal phase (120). 
 
Among premenopausal women, study findings have suggested a menstrual cycle effect 
on HPV detection based on intrapersonal variability in HPV detection observed in non-
pregnant women (121-125).  However, the evidence has been inconsistent. A few studies 
reported the follicular phase being associated with a peak in HPV detection (123-125), 
whiles others observed no association (125-127), or reported increased detection at 
midcycle (128), during luteal phase (122), or in the periovulatory phase (121). 
 
Several hypotheses have been proposed to explain the possible association between the 
menstrual cycle and HPV detection.  Estrogen may facilitate thickening and maturation 
of cervical epithelium resulting in more shedding of virus. Bacterial flora tends to be 
more stable at midcycle, which may contribute to the temporal variability observed with 




due to anti-inflammatory effects of sex hormones has also been thought to increase risk 
of HPV persistence (128, 130-135).  
 
 
Role of estrogen and progesterone in immune regulation 
Both estrogen and progesterone receptors are present on cervical epithelial cells. 
Exposure to these hormones has been suggested to influence the natural history of HPV 
infection in experimental studies.  
 
Progesterone was shown to affect immune responses by (i) skewing cytokine production 
towards a general Th2 response (136), (ii) inhibiting cytotoxic T cell activity, (iii) 
impairing NK T cell activity (137-139), (iv) reducing NK cell function and Fcγ R 
expression on monocytes and thereby impairing antibody-dependent cell cytotoxicity 
(139-141), and (iv) possibly affecting innate response by inhibiting TLR9-induced IFNγ 
production by human and mouse plasmacytoid dendritic cells (142). Mice treated with 
DMPA exhibited decreased levels of HSV-2 specific mucosal immune responses after 
intravaginal immunization with TK-HSV2 (143). Rhesus macaques treated with DMPA 
suffered from increased SIV acquisition by more than 7-fold and had significantly 
increased viral shedding during the acute phase of infection (144).   
 
The effect of estrogen can either be proinflammatory or anti-inflammatory depending on 
its concentrations (145). At low concentrations (<10
-8
M), estrogen has the ability to 




site of inflammation (139, 145). At high concentrations (>10
6
M), estrogen was shown to 
inhibit cellular immunity by impairing cytotoxic T cell activity(146) and decreasing 
migration of T cells and macrophages into the genital tract by downregulating expression 
of adhesion molecules including ICAM-1, VCAM-1 and E-selectins (139, 145).  
 
During the menstrual cycle, fluctuations in immune marker expression have been 
observed. In late follicular and ovulatory phase when estrogen level is highest, PHA-L 
stimulated PBMCs and cervical mucus from women were noted to have increased IL-10 
and decreased IL-1β expression (147). Populations of FoxP3+CD4+CD25+ T cells were 
also noted to increase in peripheral blood mononuclear cells (PBMCs) from women in 
late follicular and ovulatory phase (148).  In the luteal phase of menstrual cycle when 
progesterone concentration increases, suppression of proinflammatory cytokines 
including IL-6, TNF-α and reduced cytotoxic activity have been observed (149).  
 
Hormonal contraceptive use and host cytokine profiles 
Use of hormonal contraceptives appears to influence local cytokine profiles in cervical 
tract based on data from population studies. Current users of OCs were found to have 
increased expression of INF-γ, IL-12 as well as IL-10 in cervical secretion after 
controlling for sexual behavioral characteristics and other risk factors for HPV (150, 151). 
Another study of COC users showed increased IL-10, IL-4, IL-6 but decreased 
concentrations of IL-2, IL-12 and INF-γ (152). Such inconsistency in findings is 




variation in study designs, different sampling and testing methodologies, and 
interpersonal pharmacokinetic differences.   
 
A general pattern of suppressed proinflammatory response associated with female sex 
hormones has been reported in experimental studies. For instance, PBMCs from COC 
users were found to have lower concentrations of TNF-α (134), IFN-γ (153) and NK T 
cell activity (141). Treatment of PBMCs in vitro with biologically relevant concentrations 
of estrogen and progesterone was noted to lower expression of proinflammatory 
cytokines and increase expression of anti-inflammatory cytokines after exposure to 
HPV16 virus-like-particles (135).  
 
Current findings on cervical cytokines in relation to hormonal contraceptives are, 
however, limited in at least two ways: Most of the published findings were based on 
cervical samples collected from adolescents or young women. It is unclear how these 
findings would translate to HPV detection in older women.  In addition, cervical cytokine 
evaluation in these population studies has mostly been restricted to a few cytokines, 
which might not fully capture the activities and complex interactions of all the major 
cervical cytokines involved in the defense against HPV infection. Exploratory data on the 
levels of these other cervical cytokines in relation to HPV infection and hormonal 
contraceptive use are lacking. Further assessment in this regard is needed to facilitate 
more intensive evaluation of cervical cytokine dynamics in the setting of HPV infection.  
 





The incidence of cervical cancer is about 5-fold lower in the developed nations, e.g. U.S. 
and western Europe, relative to developing countries due to the implementation of routine 
cervical cancer screening in the population.  
 
Figure 2.5 summarizes the current recommendations for cervical screening with respect 
to different age groups in the U.S. The role of HPV testing in cervical screening has 
expanded since its first introduction in the 1990s. At present, co-testing with HPV and 
Pap smear every 5 years (preferred) or Pap testing alone every 3 years (acceptable) is 
recommended as the standard of care for women aged 30 to 65 years based on screening 
guidelines from the American Cancer Society, American Society of Colposcopy and 
Cervical Pathology, American Congress of Obstetricians and Gynecologists, and U.S. 
Preventive Services Task Force (154, 155) (Figures 2.2A, B).  
 
Recently in April 2014, the U.S. Food and Drug Administration approved the Cobas HPV 
test (Roche Diagnostics) as a primary screening tool for cervical cancer for women aged 
25 years or older, further expanding the role of HPV testing in cervical cancer prevention. 
While no formal guidelines have been issued from professional societies on the 
appropriate testing intervals for primary HPV testing, interim recommendations have 
been proposed by experts to guide clinical practice (155, 156) (Figure 2.2C).  Current 
data indicate that HPV testing alone is at least equal to Pap testing alone at 3-year 




women aged 25 to 29 years would have higher false positive rates as many young women 
have transient HPV infections that do not cause cervical dysplasia.  
 
Among older women aged over 35 years, HPV testing is part of the routine screening 
regimen for cervical cancer. A positive HPV test can be challenging to interpret in this 
age group due to a number of reasons. Study has shown a loss of correlation between 
HR-HPV test results and cytologic abnormalities as age increases, likely due to increased 
proportion of ASCUS and reduced prevalence of HR-HPV detected in older women 
(157). In addition, current understanding is limited in identifying (i) determinants of 
persistent high-risk HPV infection, (ii) biologic roles that these risk factors may play in 
the host; and (iii) whether these HPV detections represent just merely transient HPV 
detections with little potential to progress to pre-malignant or malignant lesions. 
 
Further natural history and laboratory studies are therefore warranted among older 
women (aged >35 years) to better understand the risk factors driving prevalent HPV 




A brief literature review has been provided in previous sections on the natural history of 
HPV infection, its association with cervical cancer and its association with hormonal 
contraceptive use.  The main findings and knowledge gaps are summarized in table 2.6 





Given these findings, a conceptual model showing the potential associations among 
hormonal contraceptive use, HPV detection, and the cervical immune milieu in women 
older than the age of 35 years is outlined in figure 2.3 (Figure 2.3).  
Based on this conceptual model, we proposed the following specific aims and hypotheses 
for this dissertation research conducted in pre- and perimenopausal women aged above 
35 years in the U.S.:  
Aim 1: To determine the association of hormonal contraceptive use with the 
prevalence of HPV DNA detection 
Hypothesis: Longer and more recent use of hormonal contraceptives is associated 
with higher prevalence of HPV DNA detection. 
 
Aim 2: To estimate the association between hormonal contraceptive use and 
incident HPV DNA detection 
Hypothesis: Use of hormonal contraceptives is associated with greater odds of 
incident HPV detection.  
 
Aim 3: To describe and compare differences in the host cervical cytokine profiles 
between current hormonal contraceptive users and non-current users 
Hypothesis: The cervical cytokine profile in current hormonal contraceptive users is 
disrupted and different from that seen in non-current contraceptive users. 
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TABLES AND FIGURES 
Table 2.1. Summary of prospective study findings on the association of oral contraceptive (OC) use with HPV infection 
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Marks et al 
2011 (44) 
Prospective Thailand 




COC Yes Yes Yes na Null Positive 
Vendenvelde 
et al 1992 
Prospective Belgium 










(45) 16,18, 33 
Molano et al 
2003 (46) 
Prospective Columbia 





OC No No Yes na na Negative 
Schmeink et 








OC No No No Null Null Null 
Goodman et 







OC Yes Yes Yes na Null Null 
Maucort-








OC No No Yes na na Null 
Muñoz et al 
2009 (50) 
Prospective Colombia 
Women with normal 
cytology (n=1728) 
18-85 OC No No Yes na na Null 
Lai et al 
2008 (51) 
Prospective Taiwan 




OC No Yes Yes na na Null 
Richardson et 









OC Yes No Yes na na Null 





Table 2.2. Summary of cross-sectional and case-control study findings on the association of oral contraceptive (OC) use with HPV 
prevalence 
         
Association with HPV after 
controlling for confounding 
factors 















Green et al 
2003 (61) 
Systematic 
review of 19 
studies 





N=20 509 18- 50+ OC Yes Yes Yes Null 
Vaccarella et 













Mean: 40.9 yrs 
OC Yes Yes Yes Null 





Women for routine Pap 
screening at primary 
care, STD and family 




OC No Yes Yes Positive with current OC use 







<25 to 65+  with 
no specific range 
given, 
>67% below the 
age of 44 
OC No Yes Yes Positive with current OC use  









OC No Yes Yes Positive with current OC use  









COC Yes Yes Yes 
Positive with current and  
≥6 years of use 
(with both oncogenic and any 
HPV) 





Women participating in a 




OC Yes No Yes Positive with ≥ 6 yeas of use 






presenting for routine 
pap smears (n=467) 
17-50 
Mean: 22.9 
OC Yes No Yes 















OC Yes No Yes Positive with ≥5 years of use 





(i) Age 40-50 years: 
n=1443 





Mean or median 
not given. 
OC No Yes Yes 
(i) 40-50 years: Null 
(ii) 20-29: Positive 





Women presenting for 




OC No No Yes Null 






in Beijing (n=6385) 
25-54 
Mean: 39.6 
OC No No No Null 





Women with CIN at 
baseline (n=1435) 
No range given 
Mean: 35.7  
(SD 9.8) 
OC No No No 
Null  
(only assessed HPV 16 and 18) 





Women present for 




OC No No No Null 









OC No No Yes Null 





(n=257 for analysis 
between HPV-positive 




No mean or 
median given 
COC Yes Yes Yes Null 






Women presenting at 
gynecologic or STD clinics 
(i) Age <25 years: n=1103 
(ii) Age 26-55 years: 
n=2004 
(iii) Age >55 years: n=80 
Means: 
(i) <25 yrs: 21.7 
(ii) 26-55 yrs: 
37.3 
(iii) >55 yrs: 61.6 
OC No No Yes 
Null for all groups  
(only assessed HR-HPV) 
Deacon et al 
2000 (75) 
Case-control United Kingdom 
Women from screening 




from <20 to 50+;  
Over 70% in the 
range of 25-44. 
OC Yes Yes No Null 





Women with no history 
of abnormal pap smear 




OC No No Yes Null 




Canada Women with HIV (n=375) 
16.5–77.3 
Median: 32.5 













OC Yes No Yes 
Null  
(only assessed HPV 6, 11, 16, 18) 










OC No Yes No Null 









OC No Yes Yes Null 
Hildesheim et 









OC No Yes Yes Null 





Female students  
attending university 




OC No Yes Yes Null 










OC No Yes No Null 
Agorastos et 




Women with normal 
cytology (n=226) 
20-55 
Mean or median 
not given 
OC No No No Null 











OC Yes No No Null 








OC No No No Null 





Table 2.3. Summary of cross-sectional and case-control study findings on the association between progestin-only (POC) 
contraceptive use and HPV prevalence 













et al 2011 (88) 
Pooled 












2205 women with 
cervical cancer, 
2214 matched control 
women without cervical 
cancer, 





IUD Yes No Yes Null 





Women for routine Pap 





No mean or 
median given 
DMPA No Yes Yes Positive 





(n=257 for analysis 
between HPV-positive 




No mean or 
median given 















No Yes for DMPA Yes 
Positive: DMPA and 
























Women with normal 
cytology (n=226) 
20-55 
Mean or median 
unclear 
IUD No No No Positive 









DMPA Yes Yes Yes Null 





Women presenting for 
pap smears at clinics 
15-65 
Mean: 36 










Women with CIN at 
baseline (n=1435) 
Mean: 35.7  
(SD 9.8) 
IUD No No No Null 










IUD No No No Null 






sample in Shan Xi 
(n=662) 
15-59 
60% < age of 44 
IUD No No No Null 





Women were recruited 





Over 70% in the 
range of 25-44. 
Mean, median or 




No No No Null 













Table 2.4. Summary of prospective study findings on the association between progestin-only contraceptive (POC) use and HPV 
infection 
         
Association with HPV after controlling for 
confounding factors 
Study Study type 
Study 
area(s) 

























DMPA No No No na na Positive 
Maucort-








Norplant No No No na na Null 








DMPA Yes Yes Yes Null Null Null 
Molano et al 
2003 (46) 
Prospective Columbia 





IUD No No No na na Null 
Muñoz et al 
2009 (50) 
Prospective Colombia 






IUD No No No na na Null 










IUD No Yes Yes na na Null 









Immune marker(s) assessed 
Main findings in association with HPV 
(compared to HPV-negative women) 
Study samples: Cervical secretions 
Marks et al 2011 (98) 
IFN-γ, IL-2, IL-12, IL-15, IL-4, IL-5, IL-9, IL-13, IL-10, IL-17, eotaxin, IL-
1β, IL-1rα, IL-6, IL-8, IP-10, MCP-1, MIP-1α, MIP-1β, RANTES, TNF-
α, IL-7, G-CSF, GM-CSF, basic FGF, VEGF, PDGF- bb 
Shift in T-cell associated cytokine correlation from IL-2 to eotaxin with 
HPV infection 
Elevated IL-5, IL-9, IL-13, IL-17, eotaxin, GM-CSF, and MIP-1α levels seen 
with HPV 
Guha et al 2009 (100) IL-1β, IL-6, IL-10, IL-12 IL-6 elevated in HPV+ women 
Lieberman et al 2008 (101) IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12(p40/p70), IL-13, IFN-γ No significant association 
Gravitt et al 2003 (99) IL-10, IL-12 No significant association 
Tijong et al 2001 (102) IFN-γ, TNF-α, IL-1β, IL-12p40, IL-10 Increased detection of IL-12 in HPV+ women 
Crowley-Nowick et al 2000 (103) IL-2, IL10, IL12 IL-12 elevated in HPV+ women 
Study samples: Cervical tissue 
Butsch Kovacic et al 2008 (104) 
Counts of lymphocytes, neutrophils, macrophages, plasma cells, 
eosinophils 
Increased cervical inflammation with HR-HPV  
Bemudez-Morales et al 2008 (105) IL-10 Increased IL-10 mRNA levels with HPV positivity  
Song et al 2007 (106) IL-6, IL-10, IFN-γ, TNF-α Increased IFN-γ with HPV 
Ortiz-Sanchez et al 2007 (107) CD80 and 86, IL-10 Decreased CD86 with HPV 
Fernandes et al 2005 (108) IFN-γ, TNF-α, IL-10 Increased IL-10 and IFN-γ with most HPV types except HPV 18 
Study samples: Stimulated patient-derived peripheral blood mononuclear cells 
Kemp 2010 (109) IL-6, IL-8, TNF-α, MIP-1α Lower IL-6, IL-8, TNF-α, MIP-1α in HPV+ women 
Sharma et al 2007 (110) IFN-γ, IL-2, IL-4, IL-10 Increased IL-4 and IL-10, decreased IL-2 and IFN-γ with HPV infection 
Molling et al 2007 (111) IL-2, cytotoxic T cell activity, iNKT and Treg counts Increased Treg in women with persistent HPV infection 
Seresini et al 2007 (112) CD4+ T cells, cytotoxic T cell activity, IL-4, IL-5, IL-10, IFN-γ 
Level of IFN-γ released predicts infection persistence  
Higher number of infiltrating CD4(+) and T-bet(+) T cells correlates with a 
favorable clinical outcome 
Bontkes et al 2000 (113) IL-2, memory cytotoxic T cell activity (mCTL) Association of mCTL with persistent HPV 16 infection 
Study samples: Serum/peripheral blood 
Baker et al 2011 (114) 
PBMCs: MIF, sFas, sICAM-1, Svcam-1, IL-8, TNF-α, leptin, HGF, tPAI-
1, resistin, adiponectin 
TNF-α, IL-8, sFas, resistin were elevated in women with persistent HPV 
infection 
Abike et al 2011 (115) Neopterin Lower neopterin in HPV+ women 
Kemp et al 2010 (109) 
IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17, IL-1α, IL-1β, IFN-γ, GM-
CSF, TNF-α, MCP-1, MIP-1α, IP-10, RANTES, eotaxin,G-CSF, IL-12, 
increase in systemic inflammatory cytokines and weak 





Hong et al 2010 (117) IFN-γ, IL-6, IL-10, TNF-α  No significant association with clearance of the high risk HPV infection 
Bais et al 2005 (118) 
IFN-γ, TNF-α, IL-2, IL-4, IL-10, IL-12, sTNFRI, sTNFRII, leukocyte, 
neutrophils, monocytes, lymphocytes in peripheral blood 
Higher mean plasma IL-2 in women with HR-HPV 





Table 2.6. Association of cervical HPV infection with endogenous hormonal profile and hormonal contraceptive use: main findings 
and knowledge gaps (Ref: 4-153) 
Research areas Main findings Gaps in knowledge 
 
Hormonal contraceptive use  as a risk 
factor for cervical cancer 
 
 Association has been found between long-term combined oral contraceptive 
(COC) use and increased risk of invasive cervical cancer. 
 Long-term use of progestin-only contraceptives is associated with moderately 
increased risk of invasive cervical cancer. 
 
 
 Unclear whether the association between COC and cervical cancer is 
driven by COC’s effect(s) on carcinogenesis and/or on upstream events 





Hormonal contraceptive use  as a risk 
factor for HPV infection 
 
 
 Long-term , current/recent use of oral contraceptives (OCs) was shown in 
different cohort studies to associate with  
 increased HPV prevalence, 
 increased HPV incidence,  
 increased HPV persistence.  
 Conclusions have been inconsistent across studies.   
 
 
 Paucity of prospective data among women aged 40 years or above.  
 Limited and heterogeneous findings on the associations between 
other kinds of hormonal contraceptives and HPV infection.  
 




Endogenous hormonal profile 
and HPV detection 
 
 A menstrual cycle effect on HPV detection has been suggested based on 
intrapersonal variability of HPV detection during menstrual cycle 
 Findings have been inconsistent across studies 
 Specific metrics defining menstrual cycle, e.g. serum levels of sex hormones, 
were lacking in past studies. 
 
 
 Most of the studies were small, thus limiting statistical inferences. 
 Unclear how the findings could be interpreted along with other clinical 






Hormonal contraceptive use 
and host cytokine profiles 
 
 Correlations between recent oral contraceptive use and cervical levels of INF-
γ, IL-10 and IL-12 have been reported among young women. 
 A number of past population studies were limited in using serum cytokine 
levels as surrogate markers for cervical immunity, while serum and cervical 
cytokine concentrations are not well correlated..  
 A general suppression in pro-inflammatory response due to exogenous 
progesterone and estrogen (low-dose) treatments has been observed in 
animal and in vitro models.  
 
 
 Most cytokine studies reported in literature were based on samples 
from young and not older women.  
 Most studies focused on only one or a few cytokines; unclear whether 
hormonal contraceptive use is associated with levels of other cervical 
cytokines involved in cellular immune responses, and if the association 






                            
Figure 2.1. Schematic diagram showing progression of HPV infection to pre-malignant and malignant cervical lesions.  






Figure 2.2. A and B: Current cervical cancer screening strategies for women (A) aged 21-64 years and (B) aged 30-64 years according to the 
recommendations of American Society for Colposcopy and Cervical Pathology (Ref: 154, 155). C. Screening algorithm proposed by experts as interim 
guidance for primary HPV testing (Ref: 155, 156).   
HSIL: High grade squamous intraepithelial lesion. LSIL: Low grade squamous intraepithelial lesion. High-grade lesions: HSIL, atypical glandular cells, atypical 
squamous cells that favor HSIL, and carcinomas. ASCUS: Atypical squamous cells of undetermined significance.  
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Hormonal contraceptive use has been reported to be a risk factor for invasive cervical 
cancer. Findings have been mixed on its association with HPV infection. Most data were 
drawn from women aged below 35 years.  
Objective: 
The aim of this study was to assess the association of hormonal contraceptive use with 
prevalent cervical HPV detection among pre- and perimenopausal women aged over 35 
years who have normal cytology.  
Methods: 
Data came from a prospective study conducted in women aged 35-60 years in Baltimore 
MD, USA. Primary exposures of interest were the recency and duration of overall 
hormonal contraceptive (HC) use, progestin-only contraceptive (POC) use and oral 
contraceptive (OC) use. Information was collected on HPV genotypes, history of other 
sexually transmitted infections, Pap smear diagnoses, sexual behavior as well as 
reproductive characteristics. Prevalence ratios (PRs) with 95% confidence intervals (CIs) 
were estimated using generalized linear models with Poisson regression.  
Results: 
A total of 530 peri-menopausal and pre-menopausal women (aged 35-54 years) were 
included in analyses. Baseline prevalence of any HPV and high-risk (HR)-HPV was 
16.4% and 6.4% respectively. Duration or recency of overall HC use did not yield 




Relative to never POC users, more than 5 years’ use of POCs was associated with 3-fold 
increased prevalence of any HPV after adjusting for days of menstrual cycle, number of 
lifetime sex partners, acquisition of new sex partner in last 6 months, marital status, time 
since last abnormal pap smear and history of other sexually transmitted infections in the 
last 6 months. [adjusted prevalence ratio (aPR): 3.16  (95% CI: 1.82-5.48)]. Association 
with HR-HPV was also statistically significant with long-term (>5 years) POC use [aPR: 
4.26 (95% CI: 1.60-11.30)]. Current POC use was positively associated with HR-HPV 
(aPR: 2.44 (0.99-5.99) and any HPV (aPR: 1.58 (0.94-2.65) with the estimates bordering 
on statistical significance.   
No significant association was seen between prevalent HPV infection and the recency or 
duration of OC use in this study population. 
Conclusions:  
Our findings suggest that long-term use of POCs is associated with a statistically 
significant increased risk of prevalent HPV detection independent of sexual behavior 
among women with normal cytology. POC use may have impact on the natural history of 
HPV infection before development of clinical cervical disease. Longitudinal studies are 





HPV infection is one of the most common sexually transmitted infections in the world
 
(1, 
2). Persistent infections of oncogenic HPV genotypes are believed to be a necessary but 
not sufficient cause of cervical cancer (1, 2). Factors which predispose HPV infection to 
clear or to persist are not completely understood. 
 
Long-term combined oral contraceptive (COC) use has been shown to associate with 
increased risk of invasive cervical cancer or high-grade cervical neoplasia (3-6). A meta-
analysis revealed that, relative to never users of COCs, 5 or more years of COC use is 
associated with a significant 2-fold increased risk of invasive cervical cancer after 
adjustment for other risk factors (3). More than 5 years’ use of progestin-only 
contraceptives is also associated with a slight increased risk for invasive cervical cancer 
(relative risk: 1.22 [95% CI: 1.01–1.46) (3). It remains unclear whether the association 
between hormonal contraceptive use and cervical cancer is driven by its effect(s) on 
carcinogenesis and/or on upstream events such as HPV prevalence, acquisition and 
persistence. 
 
The current understanding of the epidemiologic relationship between hormonal 
contraceptive use and HPV infection is limited in several aspects. Previous studies were 
conducted in different countries that had varied baseline HPV prevalence and screening 
practice (7). Results have been mixed across studies. Null associations or associations in 




by Pap smear history. Duration of hormonal contraceptive use, which has been shown to 
relate to risk of HPV prevalence or cervical lesion development (10, 26), was not 
adequately assessed in many previous studies. In addition, current published data on the 
association between hormonal contraceptive use and HPV infection have mostly been 
focused on the use of oral contraceptives (OCs) among women below the age of 40 years, 
or across a broad age spectrum with relatively small proportion of the study population in 
the older age group. Furthermore, few studies examined the influence of hormonal 
contraceptives other than OC or COC on HPV infection (8, 10, 14, 25, 27, 28), or 
cervical neoplasia (3, 33). 
 
The goal of this study was to evaluate the cross-sectional association between hormonal 
contraceptive use and HPV prevalence among pre- and perimenopausal women aged over 
35 years who have normal cytology in the U.S. Associations were assessed in reference 
to the duration and recency of hormonal contraceptive use including oral contraceptives 
and progestin-only contraceptives.   
 
MATERIALS AND METHODS 
Study design 
Data were obtained from an observational prospective study assessing the natural history 
of HPV during the perimenopausal transition. Women aged 35 to 60 years were recruited 
from gynecological clinics associated with the Johns Hopkins Medical Institutions in 
Baltimore, Maryland. Exclusion criteria for the parent study included the following: (i) 




unable to provide informed consent, (iv) unwilling to provide contact information, (v) 
non-English speaking. Participants were enrolled at a baseline study visit, and were 
followed every 6 months for a planned period of 2 years. The study protocols were 
reviewed and approved by the Institutional Review Board at Johns Hopkins Bloomberg 
School of Public Health, Baltimore, MD.  
 
Standardized questionnaires were administered by trained interviewers at baseline and 
follow-up visits. Parameters assessed were either shown to be associated with risk of 
HPV infection, cervical cancer risk or age-related decline in immune function to allow 
confounding control in analyses. Information was collected on (i) use of hormonal 
contraceptives including duration of use, time since last use, indications of use and brand 
names, (ii) demographic information, (iii) sexual behavioral characteristics, (iv) 
reproductive history, (v) cigarette and alcohol use, (vi) use of medications other than 
hormonal contraceptives, (vii) history of sexually transmitted infections, (viii) use of 
medications other than hormonal contraceptives.  
 
Physical examination and specimen collection  
 
A comprehensive physical examination and pelvic examination were performed at 
baseline visit. A cervical secretion specimen, liquid-based Pap smear and cervical swab 
(Digene HPV sampler kit) were obtained. Cervical secretions were collected using a 
Merocel ophthalmic sponge which was placed at 6 o’clock of the cervical os for 30 
seconds. The collected cervical sample was stored at -80 
o





Liquid-based Pap smears were performed where clinically indicated.  Results of pap 
smears were abstracted from medical records and the cytological abnormalities were 
classified based on the 2001 Bethesda classification scheme [normal, inflammation, 
ASCUS (aytpical squamous cells – undetermined significance), LSIL (low grade 
squamous intraepithelial lesion), HSIL (high grade squamous intraepitheilial lesion)].   
 
HPV DNA type-specific testing was done on cervical swab samples.  DNA was extracted 
using the QIAamp DNA Blood Kit (Qiagen, Courtaboeuf, France) according to 
manufacturer’s instructions with modification.  After extraction, 8 μls of DNA (4% of 
total volume of extracted DNA) was amplified using the PGMY09/11 L1 consensus 
primer system, which amplifies with high efficiency over 40 HPV genotypes known to 
infect the genital tract. Genotype discrimination was performed by hybridizing 40 μl of 
the PCR product to a membrane with immobilized probes targeting 37 HPV genotypes 
(HPV Linear Array Roche Molecular Systems, Roche Diagnostics, Indianapolis, IN).   
 
Measures and definition of terms  
 
Primary exposure of interest 
The primary exposure of interest was self-reported use of hormonal contraceptives at 
baseline, which include oral formulations, injections, dermal patches, intrauterine or 
intravaginal devices containing or releasing estrogen and/or progestin derivatives which 




and duration of use based on the observed distribution of outcome responses. Time since 
last use was categorized into “never user,” “current user,” “<5 years ago”, “6-10 years 
ago,” “>10 years ago.” Those who reported use within the last month were categorized as 
current users. Duration of use was examined in categories of “never user,” “≤ 1 year,” 
“1.1-5 years,” and “>5 years.” A variable combining both current and former use with 
cumulative duration of exposure was also created to study the joint effects of recency and 
duration of hormonal contraceptive use.  Long-term and short-term uses were defined as 
use for >5 and ≤5 years respectively.   
 
Secondary analyses were done with further categorizations of the hormonal contraceptive 
use: (i) oral contraceptives (OC), (ii) progestin-only contraceptives including progestin-
only pills (minipills), injectable contraceptives [depot medroxyprogesteroneacetate 
(DMPA)], etonogestrel single-rod implant, and intrauterine contraceptive containing 
levonorgestrel such as Mirena. The category of oral contraceptives included participants 
reporting the use of “combined oral contraceptives (COC)”, medication brand names that 
can be classified pharmaceutically as COC, as well as the “pill(s).” Given the generally 
accepted notion that “the pill” usually refers to combined oral contraceptive pill (34, 35), 
the category of OC likely represents mostly COC users. Sensitivity analyses were done 
categorizing only those who were able to report the specific COC medication brand 
names as COC users for comparison.  
 




The primary outcome of interest was detection of any type-specific HPV DNA in the 
cervical samples collected at baseline, which include 37 HPV types 6, 11, 16, 18, 26, 31, 
33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 
73, 81, 82, 82 subtype (IS39), 83, 84, 89 (CP6108).  
 
Secondary outcomes of interest included detection of any high-risk HPV type, which was 
defined as one of the following HPV types identified by the International Collaboration 
of Epidemiological Studies of Cervical Cancer as oncogenic (HPV types 16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, 68) (36).  
 
Other measures  
For this cross-sectional analysis, we focused on the baseline visit and selected women 
who were pre- and perimenopausal (reproductive and menopausal transition) as defined 
by the criteria proposed by the Stages of Reproductive Aging Workshop (40). Briefly, 
premenopause/reproductive age was defined as having overall regular menstrual periods 
or subtle changes of menstrual flow. Perimenopause/menopausal transition was defined 
as reporting irregular menstrual periods in the last 12 months with last menstrual period 
<12 months ago. Postmenopause was defined as >12 months since last reported 
menstrual period (40).  
 
Abnormal Pap smear was defined as having cytologic diagnoses of ASCUS, LSIL and 
HSIL. Time since last abnormal Pap smear was categorized into “never,” “<1 year ago,” 




reported genital chlamydia, gonorrhea, syphilis, herpes, trichomoniasis, chancroid, warts. 
Other variables were categorized based on frequency of distribution of outcomes of 
interest. Age was categorized into “35-39 years,” “40-44 years,” “45-49 years,” and “≥50 
years.” Race was categorized as “Caucasian,” “African American,” and “others” which 
included American Indians, Pacific Islanders, Asians and those who were unidentified. 
Number of livebirths was categorized into “0-1,” “2,” and “>2.”  Lifetime number of 
sexual partners was categorized into “1,” “2-4,” and “≥5.” Recent sex exposure was 
described by a variable on sexual activity in the past 6 months: “no sex,” “have sex but 




Analysis population  
The population eligible for analysis included participants who were pre- and 
perimenopausal who did not report use of exogenous hormones other than hormonal 
contraceptives (n=618).  Among these participants, the following subjects were excluded 
from analyses: (i) inadequate baseline HPV DNA testing result (n=1, 0.2%), (ii) missing 
information on hormonal contraceptive use (n=22, 3.6%), (iii) missing responses on 
recent history of other sexually transmitted infections (n=4, 0.7%), (iv) missing 
information on sexual behavioral risk factors (n=4, 0.7%), (v) abnormal Pap smear 
(n=35) or unclear Pap smear status (n=19) at baseline (total n=54, 8.7%), (vi) unclear 
time since last abnormal Pap smear (n=4, 0.7%). The exclusions resulted in a total of 530 





Exploratory data analysis 
Variables assessed in this study dataset were categorically coded. Distribution of 
demographic, sexual behavioral characteristics, primary outcome and exposure 
characteristics in the study population were evaluated using Pearson’s Chi-square or 
Fisher’s exact test if cell count was <5.   
 
Univariable modeling  
Characteristics found to be of significant association (p<0.05) based on Chi-square tests 
were further assessed by univariate prevalence ratios (PR). PRs estimated by a 
generalized linear model with Poisson function with robust variance were used to 
evaluate the strength of association between a given risk factor and detection of any or 
high-risk HPV. Characteristics which were shown in previous literature to be risk factors 
for any and/or high-risk HPV infections; and/or yielded statistically significant 
association or potential statistically significant association (p<0.10) in univariable models 
were considered in multivariable models.  
 
Multivariable modeling 
Selection of predictors was done by forward and backward selection of factors with cut-
off P value at 0.05. Covariates that showed >10% change in the effect size of the primary 
exposure and outcome association were kept in the final model. If supported by literature 
to be important risk factors for HPV progression, predictors which did not yield 




epidemiologic considerations even though the final model was not the most parsimonious 
model with Akaike’s information criterion values.  
 
Sensitivity analyses 
For secondary analyses with each type of hormonal contraceptive exposure, 2 sets of 
analyses with 2 different reference groups were created for comparison: (i) one reference 
group included only those who never used any hormonal contraceptives, and (ii) the other 
reference group comprised never users of any hormonal contraceptives as well as 
individuals who never used that particular type of hormonal contraceptives being 
assessed.  
 
Missing data was included as a response in the variables that had unclear or missing data, 
which included recent history of other sexually transmitted infections, sexual behavioral 
risk factors and Pap smear status. Final models were also constructed with these variables 
including these missing responses to assess the influence of missing data. Results and 
conclusions were unchanged with exclusion or inclusion of missing responses.  




Baseline characteristics of study population and association with HPV prevalence  
A total of 530 participants were included in data analyses. The mean age was 44.2 years 




more than half attained college or higher level of education. Majority of women had 2 or 
more livebirths (67.8%) and were sexually active at baseline (83.7%). Most subjects had 
multiple lifetime sex partners (88.9%). Over 60% participants claimed having more than 
5 sex partners but only 2.8% reported new sexual partners in the past 6 months. Most 
subjects were categorized as premenopausal based on their days of menstrual cycle 
(75.6%). About half of the population (45.5%) had abnormal Pap smear in the past, with 
2.1% having the diagnosis within the past year (Table 3.1).  
 
Sixteen percent (16.4%, n=87) of the study population had HPV detected, of whom 
23.0% (n=20) had infection with multiple HPV types. The overall prevalence of high-risk 
(HR) HPV was 6.4% (Table 3.1). The most common HR-HPV type detected was HPV 52, 
followed by HPV 16, 39 and 18. HPV 83, 62, and 55 were the most common low-risk 
HPV types detected in the study population (Figure 3.1).  
 
Higher HPV prevalence was observed among women reporting recent diagnoses (≤6 
months ago) of other sexually transmitted infections, having abnormal Pap smear in the 
past year, reporting new sexual partner in the past 6 months or having more than 5 
lifetime sex partners. Women who were single had more prevalent HPV infections 
detected compared with currently married women. Subjects younger than 39 years had 






After controlling for other risk factors for HPV, our final model showed that having new 
sexual exposure in the past 6 months but not multiple lifetime sex partners was 
statistically significantly associated with prevalent HPV infection (Table 3.3). Other 
independent predictors for HPV prevalence included marital status, diagnosis of 
abnormal Pap smear within the past year, and recent history of other sexually transmitted 
infections (Table 3.3).    
  
Baseline hormonal contraceptive use in study population  
Most women had used hormonal contraceptives (HCs) at some point in their lives 
(89.4%). Over half (54.4%) of women last used HCs more than 5 years ago (Table 3.2). 
Thirty-six percent (36.3%) of the study population had cumulative exposure to HCs for 
more than 5 years (n=192). 21.1% (n=112) were currently using HCs at baseline (Table 
3.2). Overall 8.9% (n=47) reported current use of progestin-only contraceptives (POCs). 
More than half of them were Mirena users (55.3%, n=26), with the rest being progestin 
pill users (n=18) and DMPA users (n=3).Among those who were long-term (> 5 years) 
ever users of POCs (n=16) (Table 3.2), majority of them were either users of DMPA 
(n=9) or Mirena (n=5). 
 
Over half of current HC users were younger than 44 years (67.0%). Forty percent of 
current HC users were either nulliparous or had only 1 livebirth. Close to half (42.5%) of 
those who used HCs solely for gynecologic conditions were current HC users.  
 





Hormonal contraceptive use in general: 
No significant association was found between HPV detection and the duration or recency 
of overall HC use in univariable or multivariable analyses (Table 3.3, Table 3.4).  
 
Progestin-only contraceptive use: 
Significantly higher proportions of long-term (>5 years) POC users (50%) were HPV-
positive than those who were short-term (20.8%) or never users (14.8%) (P=0.01) (Table 
3.2). More current users of POCs were positive for HPV (27.7%) than never users 
(14.3%) (P=0.02) (Table 3.2).   
 
Compared with never POC users, more than 5 years of POC use was associated with 
nearly 3-fold increased HPV prevalence after controlling for other independent risk 
factors including having more than 5 lifetime sex partners, reporting recent new sex 
partner, being single or divorced, being diagnosed with other sexually transmitted 
infections in the past 6 months, and having abnormal pap smears within the past year 
[adjusted prevalence ratio (aPR): 3.16  (95% CI: 1.82-5.48)] (Table 3.5). Prevalence of 
HR-HPV was also increased with long-term use of POCs compared with never POC 
users [aPR: 4.26 (95% CI: 1.6-11.3)](Table 3.5). Current POC use was positively 
associated with HR-HPV (aPR: 2.44 (0.99-5.99) and any HPV (aPR: 1.58 (0.94-2.65) 
with the estimates bordering on statistical significance after controlling for other risk 





When the reference group became never users of any HCs, more than 5 years’ use of 
POC was still found to associate with nearly 3-fold increase of any HPV prevalence after 
adjusting for other risk factors. Association with HR-HPV prevalence did not achieve 
statistical significance between long duration of use and HR-HPV prevalence (Appendix. 
Appendix Tables 3.1-3.2).   
 
Oral contraceptive use:  
Neither duration nor recency of OC use yielded statistically significant association with 
detection of any or HR-HPV at baseline after controlling for confounders, regardless of 
the reference group being never OC users or never HC users. (Table 3.7-3.8; Appendix 
Table 3.3-3.4). Similar findings were observed among users who could confirm the brand 
names of the COC they used (Appendix Tables 3.5-3.6).   
 
DISCUSSION 
Our study found that recency and duration of overall hormonal contraceptive use was not 
associated with any or HR-HPV detection in reproductive women over the age of 35 
years. Long-term (>5 years) use of POCs was observed to associate with increased risk of 
prevalent HPV infection after controlling for other risk factors. We did not detect 
significant association of OC or COC use with HPV prevalence in our study population.  
 
Previous findings on the effects of OC or COC on HPV infection have been mixed (8-32). 
Reported associations differ due to heterogeneity in study locations, measure metrics and 




which reveal neither a strong positive or negative association between OC use and HPV 
prevalent infection even after considering duration of OC use and confounding control of 
sexual activity (24, 26). Past studies that showed positive association between OC and 
HPV infection were mostly conducted in young women below the age of 40 years (8, 10, 
13, 16, 21, 22, 29, 30-32), who were likely to have different sexual behavioral profiles 
than our study population of older females (41). Furthermore, pharmacokinetic 
differences have been reported on COC and ethynl estradiol in human subjects with 
different ethnic backgrounds (42-45). The bioavailable doses of estrogen derivatives may 
therefore be greater in certain populations than others. If dosage of OC or COC has an 
impact on HPV infection, the different bioavailabilities of exogenous estrogen derivatives 
may result in positive association observed between OC or COC and HPV in certain 
ethnic populations but not in others.  
 
Our finding on POC use and HPV infection is also consistent with recent studies 
conducted among younger women in the U.S., which reported positive associations 
between injectable contraceptive use and HPV prevalence (25, 27, 28). Prospective 
studies examining the effects of POCs on HPV have been relatively scarce with mixed 
findings (8, 14, 27). A recent study did not find significant association between DMPA 
use and HPV prevalence, persistence or incidence in Thai young females (8). In the U.S., 
one large cohort study showed that 6-month persistence of HPV infection was mildly 
elevated among users of injectable contraceptives [OR: 1.15 (95% CI: 1.01-1.32)] who 
had low-grade or equivocal cytological abnormalities (14). Another U.S. study reported 




controlling for sexual behavioral factors (adjusted OR: 7.3; 95% CI, 1.5-35.5)(27). Type-
specific HPV persistence, however, was not found in the latter study (27), suggesting that 
DMPA use might be associated more with new HPV detection than persistence in that 
study population.  
DMPA use was postulated to promote HPV infection as it was found to associate with 
atrophic cervical epithelium as well as different degrees of nuclear atypia (46, 47). The 
compromise of the epithelial barrier may facilitate the seeding and establishment of viral 
agents such as HPV. In addition, DMPA use was found to associate with acquisition of 
chlamydial infection (48-51), which is proposed to be a cofactor for HPV infection (48-
50).  
 
Female sex hormones have been suggested to influence host immunity and viral 
replication (52). Progesterone has been shown to inhibit cytotoxic T lymphocyte activity 
and perforin expression on T cells (52). Progesterone also has impact on cytokine 
production that generally skews towards Th2 response (52, 53). In addition, progesterone 
and glucocorticoid hormones have been found to increase HPV viral mRNA and 
significantly stimulate HPV viral replication in vitro (54, 55).  
Cumulative exposure to POCs may also be influenced by dosages of progesterone 
administration. Previous study noted that while DMPA (a high-dose POC) was associated 
with increased HPV persistence, use of Norplant (a low-dose POC) was not (14). Our 
study was limited in sample size and statistical power to examine the respective 
associations of different kinds of POC use with HPV prevalence, which is an area 





Our study has a number of strengths. Extensive data were collected on the status, types, 
recency and duration of hormonal contraceptive use. This allowed more specific 
characterization of exogenous sex hormone exposure as well as its association with HPV 
infection. Detailed information was also obtained on sexual behavior and other risk 
factors to assess covariates that may confound the associations between HPV prevalence 
and hormonal contraceptive use. Menopausal stages were determined biologically based 
on days of menstrual cycle which lent relevance to the actual endogenous female sex 
hormonal levels in the subjects. In addition, our study population had a baseline racial 
demographic that was generally representative of the U.S. population in this age range 
(56, 57). Lifetime and recent sexual behavioral characteristics also correlated well with 
recent estimates of the U.S. national sample in this age group (41), thus enhancing the 
relevance of our findings to the population from which they were sampled.  
 
Our study also has its limitations. Participants in this study were recruited from women 
presenting to gynecological clinics who were routinely screened with Pap smears. The 
generalizability of our results to the general older female population may thus be limited. 
The HR-HPV prevalence in our population (6.4%) was comparable to the multi-site 
estimate (9%) reported by Centers for Disease Control and Prevention for women aged 
over 30 years who had normal cervical cytology and presented to clinics for cervical 
screening in the U.S (58). The prevalence findings in such clinic population, however, 
varied from some other population estimates due to differences in study demographics 




meta-analysis done by Bruni et al found an almost 3-fold lower level of overall HPV 
prevalence among North American women with normal Pap smears in this age group (7). 
The difference may be attributable to the inclusion of a large study composing of a 
significantly higher proportion of Asians compared with national samples (7, 59), and 
Asians were generally found to have lower HPV prevalence than other ethnic groups (7). 
Our HR-HPV prevalence was lower than that (27% for age 30- 59 years) found from the 
National Health and Nutrition Examination Survey (NHANES), which oversampled 
African Americans and Hispanics and used a more liberal definition of HR-HPV (60, 61). 
Such difference in prevalence estimate is also due to the ability of the laboratory protocol 
used in the NHANES study to detect very low levels of HPV DNA (60). Supposing that 
our study was less sensitive in HPV detection, our findings may have underestimated the 
magnitude of the actual outcome prevalence. False negatives and type II error are higher, 
thereby limiting our power to detect a potential association if it exists.      
The directionality of the association observed in our study is, however, still expected to 
be applicable to the general population, assuming there was minimal selection bias and 
unmeasured or residual confounding.  One of the implications of assessing hormonal 
contraceptive use as determinant of HPV detection was to improve testing-associated 
counseling of women who were being screened for cervical cancer. Given that, our study 
population was most relevant to our target population, and the results of our study were 
generalizable to the target population. 
 
We were limited on self-reported data on hormonal contraceptive use. There was 




conditions. These might introduce misclassification of exposure which would bias the 
estimates of associations.  However, previous studies comparing self-reported 
contraceptive use to clinical records in women aged 20 to 42 years have shown relatively 
high agreement (61), especially with regard to the duration and hormonal composition of 
current and recent use (62, 63). The amount of misclassification introduced by 
discrepancies in self-report of recent use of hormonal contraceptives would thus be 
relatively small, which would likely not obscure the directionality of associations seen in 
this study.  
 
Our study was also limited on self-report for information on sexual risk behaviors, 
making the observed associations subject to potential unmeasured and residual 
confounding.  This study was conducted in an older age group who were found to be 
generally less sexually active than younger females (41). Our data also showed that few 
reported new recent sex exposure prior to baseline (2.8%). The confounding effect of 
unmeasured sexual behavior on the associations assessed would therefore likely be 
reduced compared to the younger populations assessed in previous studies.  
In conclusion, we found that long-term use of POCs was associated with increased 
prevalence of HPV infection in pre- and perimenopausal women above the age of 35 
years in the U.S. No significant association was observed between OC use and HPV 
prevalence in this population. Since prevalence is determined by both incidence and 
duration of diseases, longitudinal studies are needed to better determine the long-term 
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TABLES AND FIGURES 
Table 3.1. Baseline characteristics of study population (N=530) 
 
















Demographic characteristics        
Age (years)    0.12   0.02 
35-39  126 (23.8) 29 (23.0)   15 (11.9)  
40-44  148 (27.9) 19 (12.8)   10 (6.8)  
45-49  157 (29.6) 22 (14.0)   6 (3.8)  
≥50  99 (18.7) 17 (17.2)   3 (3.0)  
        
Race    0.36   0.68 
Caucasian  392 (74.0) 60 (15.3)   23 (5.9)  
African American  99 (18.7) 21 (21.2)   8 (8.1)  
Others c  39 (7.4) 6 (15.4)   3 (7.7)  
        
Education status    0.01   0.12 
High school  84 (15.9) 8 (9.5)   4 (4.8)  
Post-high school  122 (23.0) 30 (24.6)   13 (10.7)  
College graduate  166 (31.3) 30 (18.1)   11 (6.6)  
Post-college  158 (29.8) 19 (12.0)   6 (3.8)  
        
Marital status    <0.001   0.005 
Married  339 (64.0) 35 (10.3)   13 (3.8)  
Single  107 (20.2) 33 (30.8)   12 (11.2)  
Divorced/separated/widowed  84 (15.9) 19 (22.6)   9 (10.7)  
        
Current smoker    0.71   0.39 
No  475 (89.6) 77 (16.2)   29 (6.1)  
Yes  55 (10.4) 10 (18.2)   5 (9.1)  
        
Parity    0.02   0.73 
0 or 1  170 (32.1) 39 (22.9)   13 (7.7)  
2  124 (23.4) 14 (11.3)   7 (5.7)  
>2  235 (44.4) 34 (14.5)   14 (6.0)  
        
Sexual behavioral characteristics        




≤2  59 (11.1) 5 (8.5)   3 (5.1)  
3-4  134 (25.3) 14 (10.5)   6 (4.5)  
5-6  215 (40.6) 43 (20.0)   16 (7.4)  
>10  122 (23.0) 25 (20.5)   9 (7.4)  
        
Sexual activity in last 6 months    <0.001   <0.001 
No sex  86 (16.2) 12 (14.0)   5 (5.8)  
Have sex but no new sexual partner  429 (80.9) 67 (15.6)   22 (5.1)  
Have sex with new sexual partner  15 (2.8) 8 (53.3)   7 (46.7)  
        
Last menstrual period (days)    0.18   0.70 
1-14  227 (42.8) 46 (20.3)   14 (6.2)  
15-28  174 (32.8) 26 (15.0)   13 (7.5)  
28-40  34 (6.4) 4 (11.8)   3 (8.8)  
40-365  95 (17.9) 11 (11.6)   4 (4.2)  
        
Ever undergone colposcopy    0.60   0.06 
No  425 (80.2) 68 (16.0)   23 (5.4)  
Yes  105 (19.8) 19 (18.1)   11 (10.5)  
        
Time since last abnormal pap smear    0.06   0.12 
Never had abnormal pap smear  289 (54.5) 43 (14.9)   13 (4.5)  
<1 year ago  11 (2.1) 5 (45.5)   2 (18.2)  
2-5 years ago  59 (11.1) 11 (18.6)   4 (6.8)  
≥6 years ago  171 (32.3) 28 (16.4)   15 (8.8)  
        
Diagnosed with other sexually transmitted infections  in the 
past 6 months d 
    
0.03 
   
0.10 
No  517 (94.5) 80 (15.5)   32 (6.2)  
Yes  13 (5.5) 7 (53.9)   2 (15.4)  
a. Percentages or numbers in categories may not add up to 100% or the total number due to missing data.  
b. HR-HPV types: oncogenic HPV as defined as types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 (IARC 2007). 
c. Other categories include American Indian (n=2), Pacific Islander (n=2), Asian (n=16), unidentified (n=9).  







Table 3.2. Baseline hormonal contraceptive use and HPV detection in study population (N=530) 
 




Any HPV+  



















      
Duration of use by recency Years   0.58   0.19 
 Never used any HC  56 (10.6) 7 (12.5)   4 (7.1)  
Current  ≤5 82 (15.5) 16 (19.5)   6 (7.3)  
 >5  30 (5.9) 8 (25.8)   4 (12.9)  
Former ≤5 179 (33.8) 26 (14.5)   12 (6.7)  
 >5  161 (30.4) 26 (16.2)   5 (3.1)  
Unclear duration  22 (4.0) 4 (19.1)   3 (14.3)  
        
Time since last use    0.35   0.57 
 Never user   56 (10.6) 7 (12.5)   4 (7.1)  
Current user   112 (21.1) 24 (21.4)   10 (8.9)  
Last use ≤ 5 years ago  74 (14.0) 11 (14.9)   2 (2.7)  
Last use  6-10 years ago  63 (11.9) 13 (20.6)   4 (6.4)  
Last use >10 years ago  225 (42.5) 32 (14.2)   14 (6.2)  
        
 
Use of any progestin-only contraceptives 
 













 Never used any progestin-only 
contraceptives 
 440 (83.0) 63 (14.3)   24 (5.5)  
 ≤5 72 (13.6) 15 (20.8)   5 (6.9)  
 >5  16 (3.0) 8 (50.0)   4 (25.0)  
Cannot be determined  2 (0.4) 1 (50.0)   1 (50.0)  
        
Time since last use     0.02   0.11 
 Never used any progestin-only 
contraceptives 
 440 (83.0) 63 (14.3)   24 (5.5)  
Current user   47 (8.9) 13 (27.7)   6 (12.8)  
Past user  43 (8.1) 11 (25.6)   4 (9.3)  
        
 
Use of oral contraceptives  
 
 
   
 













 Never used any oral contraceptives  95 (17.9) 21 (22.1)   10 (10.5)  
 ≤5 211 (39.8) 32 (15.2)   14 (6.6)  
 >5  197 (37.2) 30 (15.2)   7 (3.6)  
Cannot be determined  27 (5.1) 4 (14.8)   3 (11.1)  
        
Time since last use     0.25   0.19 
 Never used any oral contraceptives  95 (17.9) 21 (22.1)   10 (5.1)  
Current user   63 (11.9) 10 (15.9)   4 (6.4)  
Past user   372 (70.2) 56 (15.1)   20 (5.4)  
        
a. Percentages or numbers in categories may not add up to 100% or the total number due to missing data.  




 Table 3.3.Association between HPV detection and total exposure to any hormonal contraceptives (N=530) 
    Positive for any HPV 
n=87 (16.4%) 




  Total N 
N(col %) 
Any HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
 Adjusted  




PR (95% CI) 
 Adjusted  
PRa (95% CI) 
 
Use of hormonal contraceptives 
 
 






           
 Never user    56 (10.6) 7 (12.5) Ref  Ref  4 (7.1) Ref  Ref 
Current user ≤5  82 (15.5) 16 (19.5) 1.56 (0.69-3.55)  1.18 (0.52-2.71)  6 (7.3) 1.02 (0.30-3.47)  0.87 (0.25-3.06) 
 >5   30 (5.9) 8 (25.8) 2.06 (0.83-5.16)  1.59 (0.65-3.87)  4 (12.9) 1.81 (0.48-6.73)  0.92 (0.20-4.27) 
Past user  ≤5  179 (33.8) 26 (14.5) 1.16 (0.53-2.53)  0.96 (0.45-2.03)  12 (6.7) 0.94 (0.31-2.80)  0.83 (0.28-2.41) 
 >5   161 (30.4) 26 (16.2) 1.29 (0.59-2.81)  1.27 (0.59-2.73)  5 (3.1) 0.43 (0.12-1.56)  0.38 (0.11-1.29) 
Unclear duration   22 (4.0) 4 (19.1) 1.52 (0.50-4.68)  1.07 (0.39-2.94)  3 (14.3) 2.00 (0.49-8.21)  1.24 (0.32-4.85) 
            
Time from last menstrual period             Days                           
1-14  227 (42.8) 46 (20.3) Ref  Ref  14 (6.2) Ref  Ref 
15-28  174 (32.8) 26 (15.0) 0.74 (0.48-1.14)  0.70 (0.45-1.09)  13 (7.5) 1.21 (0.58-2.51)  1.18 (0.58-2.41) 
28-40  34 (6.4) 4 (11.8) 0.58 (0.22-1.51)  0.71 (0.26-1.95)  3 (8.8) 1.43 (0.43-4.73)  1.74 (0.50-6.13) 
40-365  95 (17.9) 11 (11.6) 0.57 (0.31-1.06)  0.56 (0.30-1.03)  4 (4.2) 0.68 (0.23-2.02)  0.68 (0.24-1.97) 
            
Lifetime number of sexual partners            
≤2  59 (11.1) 5 (8.5) Ref  Ref  3 (5.1) Ref  Ref 
3-4  134 (25.3) 14 (10.5) 1.23 (0.46-3.27)  1.08 (0.41-2.87)  6 (4.5) 0.88 (0.23-3.40)  0.65 (0.18-2.35) 
≥5  337 (63.6) 68 (20.2) 2.38 (1.01-5.66)  1.56 (0.65-3.75)  25 (7.4) 1.46 (0.45-4.68)  0.81 (0.25-2.67) 
            
Sexual activity in last 6 months            
No sex  86 (16.2) 12 (14.0) Ref  Ref  5 (5.8) Ref  Ref 
Have sex but no new sexual 
partner 
 429 (80.9) 67 (15.6) 1.12 (0.63-1.98)  1.69 (0.96-2.96)  22 (5.1) 0.88 (0.34-2.27)  1.11 (0.43-2.92) 
Have sex with new sexual partner  15 (2.8) 8 (53.3) 3.82 (1.89-7.75)  3.25 (1.51-7.03)  7 (46.7) 8.03 (2.93-22.02)  6.24 (2.05-19.00) 
            
Marital status            
Married  339 (64.0) 35 (10.3) Ref  Ref  13 (3.8) Ref  Ref 
Single  107 (20.2) 33 (30.8) 2.99 (1.96-4.56)  2.83 (1.82-4.43)  12 (11.2) 2.92 (1.38-6.22)  2.01 (0.84-4.85) 








Time since last abnormal pap smear 
Never  289 (54.5) 43 (14.9) Ref  Ref  13 (4.5) Ref  Ref 
< 1 year ago  11 (2.1) 5 (45.5) 3.05 (1.51-6.18)  2.60 (1.35-5.02)  2 (18.2) 4.04 (1.03-15.79)  3.29 (0.81-13.27) 
2-5 years ago  59 (11.1) 11 (18.6) 1.25 (0.69-2.28)  0.94 (0.52-1.72)  4 (6.8) 1.51 (0.51-4.47)  1.08 (0.35-3.34) 
≥ 6 years ago  171 (32.3) 28 (16.4) 1.10 (0.71-1.70)  0.81 (0.53-1.24)  15 (8.8) 1.95 (0.95-4.00)  1.54 (0.75-3.16) 
            
Been diagnosed with other STIs in the past 6 
months 
           
No  517 (94.5) 80 (15.5) Ref  Ref  32 (6.2) Ref  Ref 
Yes  13 (5.5) 7 (53.9) 3.48 (2.02-5.99)  3.47 (1.94-6.21)  2 (15.4) 2.48 (0.66-9.30)  2.02 (0.54-7.63) 
            
a Adjusted for days from last menstrual period, number of lifetime sex partners, acquisition of new sex partner in last 6 months, marital status, time since last abnormal pap smear,  history of 









Table 3.4. Association between HPV detection and last time of use of hormonal contraceptives (N=530) 
    Positive for any HPV 
n=87 (16.4%) 




 Total N 
N(col %) 
 Any HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
 Adjusted  
PRa (95% CI) 
 HR-HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
 Adjusted  
PRa (95% CI) 
 





           
 Never user   56 (10.6)  7 (12.5) Ref  Ref  4 (7.1) Ref  Ref 
Current user   112 (21.1)  24 (21.4) 1.71 (0.78-3.74)  1.29 (0.59-2.83)  10 (8.9) 1.25 (0.41-3.81)  0.88 (0.27-2.90) 
Last use ≤ 5 years ago  74 (14.0)  11 (14.9) 1.19 (0.49-2.87)  0.83 (0.35-1.97)  2 (2.7) 0.38 (0.07-2.00)  0.28 (0.05-1.50) 
Last use  6-10 years ago  63 (11.9)  13 (20.6) 1.65 (0.71-3.85)  1.52 (0.65-3.59)  4 (6.4) 0.89 (0.23-3.39)  0.78 (0.20-3.06) 
Last use >10 years ago  225 (42.5)  32 (14.2) 1.14 (0.53-2.44)  1.07 (0.51-2.23)  14 (6.2) 0.87 (0.30-2.55)  0.79 (0.27-2.29) 
             
a Adjusted for days from last menstrual period, number of lifetime sex partners, acquisition of new sex partner in last 6 months, marital status, time since last abnormal pap smear,  history 











Table 3.5. Association between HPV detection and total exposure to any progestin-only contraceptives, with never users of 
progestin-only contraceptives as reference group  (N=530) 
 
 
   Positive for any HPV 
n=87 (16.4%) 




 Total N 
N(col %) 
 Any HPV+ 
n(row %) 
Unadjusted  
PR (95% CI) 
 Adjusted  
PRa (95% CI) 
 HR-HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
 Adjusted  
PRa (95% CI) 
 
Use of progestin-only 
contraceptives 
            
 
   Total duration of use 
 
Years 
           
 Never user  440 (83.0)  63 (14.3) Ref  Ref  24 (5.5) Ref  Ref 
Ever user              
 ≤5  72 (13.6)  15 (20.8) 1.46 (0.88-2.41)  1.17 (0.70-1.96)  5 (6.9) 1.27 (0.50-3.23)  1.32 (0.52-3.35) 
 >5 16 (3.0)  8 (50.0) 3.49 (2.03-5.99)  3.16 (1.82-5.48)  4 (25.0) 4.58 (1.80-11.67)  4.26 (1.60-11.30) 
Unclear duration  2 (0.4)  1 (50.0) 3.49 (0.86-14.25)  2.06 (0.73-5.77)  1 (50.0) 9.17 (2.17-38.72)  5.46 (1.07-27.83) 
             
a Adjusted for days from last menstrual period, number of lifetime sex partners, acquisition of new sex partner in last 6 months, marital status, time since last abnormal pap smear,  history of 







Table 3.6. Association between HPV detection and recency of any progestin-only hormonal contraceptive use, with never users of 
progestin-only contraceptives as reference group (N=530) 
   
 
 Positive for any HPV 
n=87 (16.4%) 




 Total N 
N(col %) 
 Any HPV+ 
n(row %) 
Unadjusted  
PR (95% CI) 
 Adjusted  
PRa (95% CI) 
 HR-HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
 Adjusted  
PRa (95% CI) 
 
Use of progestin-only 
contraceptives 
            
             
Last time of use             
 Never user  440 (83.0)  63 (14.3) Ref  Ref  24 (5.5) Ref  Ref 
Current user   47 (8.9)  13 (27.7) 1.93 (1.15-3.24)  1.58 (0.94-2.65)  6 (12.8) 2.34 (1.01-5.44)  2.44 (0.99-5.99) 
Past user  43 (8.1)  11 (25.6) 1.79 (1.02-3.13)  1.51 (0.88-2.61)  4 (9.3) 1.71 (0.62-4.69)  1.65 (0.69-3.96) 
             
a Adjusted for days from last menstrual period, number of lifetime sex partners, acquisition of new sex partner in last 6 months, marital status, time since last abnormal pap smear,  history 






Table 3.7. Association between HPV detection and total exposure to any oral contraceptives, with never users of oral 
contraceptives as reference group  (N=530) 
     Positive for any HPV 
n=87 (16.4%) 




  Total N 
N(col %) 
 Any HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
 Adjusted  
PRa (95% CI) 
 HR-HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
 Adjusted  
PRa (95% CI) 
 
Use of oral contraceptives  
             
 
   Total duration of use 
 
Years 
            
 Never user   95 (17.9)  21 (22.1) Ref  Ref  10 (10.5) Ref  Ref 
Ever user  ≤5   211 (39.8)  32 (15.2) 0.69 (0.42-1.13)  0.69 (0.43-1.11)  14 (6.6) 0.63 (0.29-1.37)  0.63 (0.29-1.37) 
 >5  197 (37.2)  30 (15.20 0.69 (0.42-1.14)  0.77 (0.47-1.27)  7 (3.6) 0.34 (0.13-0.86)  0.34 (0.13-0.86) 
 Unclear  27 (5.1)  4 (14.8) 0.67 (0.25-1.79)  0.61 (0.26-1.44)  3 (11.1) 1.06 (0.31-3.57)  1.06 (0.31-3.57) 
              
a Adjusted for days from last menstrual period, number of lifetime sex partners, acquisition of new sex partner in last 6 months, marital status, time since last abnormal pap smear,  







Table 3.8. Association between HPV detection and recency of any oral contraceptive use, with never users of oral 
contraceptives as reference group (N=530) 
    Positive for any HPV 
n=87 (16.4%) 




 Total N 
N(col %) 
 Any HPV+ 
n(row %) 
Unadjusted  
PR (95% CI) 
 Adjusted  




PR (95% CI) 
 Adjusted  
PRa (95% CI) 
 
Use of oral contraceptives 
            
 
  Time since last use 
 
 
           
 Never user  95 (17.9)  21 (22.1) Ref  Ref  10 (5.1) Ref  Ref 
Current user   63 (11.9)  10 (15.9) 0.72 (0.36-1.42)  0.67 (0.34-1.30)  4 (6.4) 0.60 (0.20-1.84)  0.44 (0.13-1.51) 
Past user   372 (70.2)  56 (15.1) 0.68 (0.43-1.07)  0.73 (0.47-1.12)  20 (5.40 0.51 (0.25-1.06)  0.52 (0.26-1.04) 
             
a Adjusted for days from last menstrual period, number of lifetime sex partners, acquisition of new sex partner in last 6 months, marital status, time since last abnormal pap smear,  
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Long-term and recent use of combined oral contraceptives was suggested to associate 
with increased risk of cervical cancer. Study findings on the association between 
hormonal contraceptive use and HPV infection have been inconsistent. Most published 
data were drawn from women aged below 35 years. Little is known about the effect of 
hormonal contraceptive use on HPV detection in older women.   
Objective: 
The aim of this study was to assess the association of hormonal contraceptive use with 
new detection of HPV among pre- and perimenopausal women aged over 35 years who 
had normal cervical cytology. Secondary analysis was also done to compare the 
proportions of positive HPV detections which had persistent detection at next follow-up. 
Methods: 
Five hundred and thirty pre- and perimenopausal women (aged 35-54 years) were 
recruited from gynecologic clinics in Baltimore, MD. Subjects were followed semi-
annually. Assessment was made on cervical HPV genotypes, cervical cytology, sexual 
behavior, demographic factors and use of hormonal contraceptives. Persistent HPV 
detection was defined as repeated detection of HPV at next follow-up visit as compared 
with previous visit. Incident detection was defined as any type-specific HPV which was 
detected at current visit but not at previous visit. Association between hormonal 
contraceptive use and incident HPV detection was measured by odds ratios (ORs) with 
95% confidence intervals (CIs) estimated in generalized estimating equation models. 





Median follow-up time was 19.1 months with an interquartile range of 7.3 months. 
Seventy new cases of HPV and twenty-nine incident cases of high risk (HR)-HPV were 
observed. Relative to never users of progestin-only contraceptives (POCs), current use of 
POCs were found to associate with new HR-HPV detection [adjusted odds ratio (aOR): 
3.24 (95% CI: 1.37-7.65) after controlling for days of menstrual cycle, number of lifetime 
sex partners, acquisition of new sex partner in last 6 months, marital status and time since 
last abnormal pap smear. No statistically significant association was detected between 
incident HPV detection and current use of oral contraceptives (OCs)[aOR: 0.57 (95% CI: 
0.20-1.64)]. There was no significant association observed between duration of use of 
overall hormonal contraceptives and OCs. Association between incident HPV detection 
and duration of use of POCs was not assessed due to power limitations.   
Among 179 positive HPV cases detected in this analysis, 61% remained HPV-positive at 
next follow-up visit. No significant difference in proportions with persistent infection was 
seen by duration or recency of hormonal contraceptive use.   
Conclusions:  
Our study suggested that current use of POCs was potentially associated with increased 
risk of incident HPV detection in short-term follow-up among pre- and perimenopausal 
women over the age of 35 years.  Longer follow-up may be needed to better assess the 





Persistent infections of oncogenic HPV genotypes are believed to be a necessary but not 
sufficient cause of cervical cancer (1, 2). Aging (3, 4, 5) and alterations of host hormonal 
profile (6, 7, 8) have been implicated to play important roles in host immunity against 
viral infections. While long-term use of hormonal contraceptives has been demonstrated 
to increase risk of cervical cancer and persistent HPV infection (9, 10), most of the data 
were based on young female population. Few studies have looked at the effects of 
hormonal contraceptives on the early natural history of HPV in perimenopausal women, 
whose sexual behavioral and endogenous hormonal profiles are likely to be different than 
those of younger women. It is known that HPV prevalence peaks in the first few years 
after sexual debut and then declines afterwards. A second peak in prevalence has been 
observed at around the age of menopause in several populations in 5 world regions (2, 
11). It is unclear what factors influence HPV detection in older women that might explain 
this second peak of HPV prevalence.  
 
Data on determinants of HPV at older ages have been limited. Castle et al conducted a 
prospective study among women aged from 18 to over 65 years old in Guancaste, Costa 
Rica and noted that acquisition of HPV types decreased significantly as women aged, 
with the highest peak observed in young women and a secondary minor peak seen in 
older women (3). Gonzalez et al evaluated in a nested case-control study the sexual 
behavior and cellular immune response of women aged 45-75 years to HPV 16 virus-like 
particles (VLP), and reported that weaker immune response increased risk of HPV 




peripheral blood mononuclear cells (PBMCs) to HPV LI virus-like particles (VLPs) 
decreased in association with HPV persistence as well as increased age (age ≥65 years), 
with new HPV detection observed during follow-up among those who reported no sexual 
activity prior to follow-up screening (5). 
 
The second peak in HPV prevalence observed at older ages in several populations has 
been postulated to arise via a number of pathways, including increased incidence due to 
new infections, longer persistence of HPV infections, increased detectability of infections 
due to cervical/vaginal changes associated with aging, and reactivation of latent 
infections associated with age-related immunologic and/or hormonal changes (4, 13, 14-
17). Trends of HPV prevalence in succeeding birth cohorts were also hypothesized to be 
a contributing factor (4, 12, 13).  
 
Our previous data showed that long-term use of progestin-only contraceptives (POCs) 
was associated with 3-fold increased prevalence of any HPV in women older than 35 
years in the U.S. In this study, we aimed to assess with short-term prospective follow-up 
data the association of hormonal contraceptive use with new detection of HPV among 
pre- and perimenopausal women aged over 35 years who had normal cervical cytology. 
Secondary analysis was also done to compare the proportions of positive HPV detections 
by hormonal contraceptive use which had persistent detection at next follow-up visit. 
  





This was an observational prospective study assessing the natural history of HPV during 
the perimenopausal transition. Women aged 35 to 60 years were recruited from 
gynecological clinics associated with the Johns Hopkins Medical Institutions in 
Baltimore, Maryland. Exclusion criteria for the parent study included the following: (i) 
history of hysterectomy, organ transplant or HIV infection, (ii) currently pregnant, (iii) 
unable to provide informed consent, (iv) unwilling to provide contact information, (v) 
non-English speaking. The study protocols were reviewed and approved by the 
Institutional Review Board at Johns Hopkins Bloomberg School of Public Health, 
Baltimore, MD.  
Women were followed every 6 months. Standardized questionnaires were administered 
by trained interviewers at baseline and follow-up visits. Information was collected on (i) 
use of hormonal contraceptives including duration of use, time since last use, indications 
of use and brand names, (ii) demographic information, (iii) sexual behavioral 
characteristics, (iv) reproductive history, (v) cigarette and alcohol use, (vi) use of 
medications other than hormonal contraceptives, (vii) history of sexually transmitted 
infections.  
 
Physical examination and specimen collection  
A comprehensive physical examination, as well as pelvic examination if indicated, was 
performed at baseline visit. A cervical secretion specimen, liquid-based Pap smear and 
cervical swab (Digene HPV sampler kit) were obtained. Cervical secretions were 









Liquid-based Pap smears were performed where clinically indicated.  Results of pap 
smears were abstracted from medical records and the cytological abnormalities were 
classified based on the 2001 Bethesda classification scheme [normal, inflammation, 
ASCUS (aytpical squamous cells – undetermined significance), LSIL (low grade 
squamous intraepithelial lesion), HSIL (high grade squamous intraepitheilial lesion)].   
 
HPV DNA type-specific testing was done on cervical swab samples.  DNA was extracted 
using the QIAamp DNA Blood Kit (Qiagen, Courtaboeuf, France) according to 
manufacturer’s instructions with modification.  After extraction, 8 μls of DNA (4% of 
total volume of extracted DNA) was amplified using the PGMY09/11 L1 consensus 
primer system, which amplifies with high efficiency over 40 HPV genotypes known to 
infect the genital tract. Genotype discrimination will be performed by hybridizing 40 μl 
of the PCR product to a membrane with immobilized probes targeting 37 HPV genotypes 
(HPV Linear Array Roche Molecular Systems, Roche Diagnostics, Indianapolis, IN).   
 
Measures and definition of terms  
Primary exposure of interest 
Visits were assessed in consecutive pairs. The primary exposure variables being 
measured were current use of (i) any hormonal contraceptives, (ii) progestin-only 




included participants reporting the use of “combined oral contraceptives (COC)”, 
medication brand names that can be classified pharmaceutically as COC , as well as the 
“pill(s),” which are usually referred to as COCs based on generally accepted notion (18, 
19). Duration of use of any hormonal contraceptives and OCs were assessed in secondary 
analyses.  
 
Outcome of interest 
Primary outcome variables were evaluated against the exposure variables: (i) new 
detection of any HPV type in cervical sample which was not found at previous visit; (ii) 
new detection of any 1 of the 13 oncogenic HPV types in cervical samples which was not 
found at previous visit. Hence participants would be at risk at every visit for new HPV-
type-specific infection that was not detected in previous visit. Oncogenic HPV types were 
defined as HPV types16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 as proposed by the 
International Agency for Research on Cancer (20).  
Secondary outcome of interest was repeated detection of any HPV type that was found at 
previous visit. Positive HPV cases included both prevalent baseline detection of HPV and 
new detection of HPV during follow-up.  
 
Other measures  
All variables were coded categorically. For incidence and persistence analyses, the 
following characteristics were coded as time-varying factors: (i) primary exposure 
variables including current use of any hormonal contraceptives, POCs and OCs, (ii) 




history of other sexually transmitted infections within 6 months prior to visit, (v) marital 
status, (vi) smoking status.  Others factors assessed were treated as time-fixed variables 
as defined at baseline, which included demographic characteristics such as age, race, 
parity, lifetime number of sexual partners, history of colposcopy and time since last 
abnormal Pap smear.   
 
Statistical analysis  
Analysis population  
A total of 1244 visit pairs were observed during follow-up. Population or visits eligible 
for analysis included those who (i) had at least 6-month follow-up (n=383, 72.3% of 
population at baseline), (ii) remained cytologically normal during follow-up (n=519, 
97.9%), and (iii) visits that were associated with pre- or perimenopausal status (n=1057, 
85%). The following visits were excluded from the visit-pair analyses: (i) visits with 
missing menopausal status (n=23, 1.9%), (ii) visits with missing recent sexual behavioral 
information (n=101, 8.1%) 
 
Univariable and multivariable modeling  
Generalized estimating equation (GEE) models were used to obtain the odds ratios with 
95% confidence intervals for incident HPV detection during follow-up for the average 
subject population. Exchangeable correlation was fit with the assumption of same 
correlation between any pair of observations. Covariates which yielded statistically 
significant association or potential statistically significant association (p<0.10) in 




adjusted odds ratio for the association between the primary exposure and outcome event 
of interest.  
Selection of predictors was done by forward and backward selection of factors with cut-
off P value at 0.05. Participants’ demographic characteristics, baseline reproductive 
health history, sexual behavioral factors, and primary partner characteristics were 
assessed as potential confounding factors. Variables were defined as confounders if the 
odds ratio for the primary exposure variable changed by ≥10% when the variable was 
added to the primary model. These confounders were retained in final multivariable 
models. If supported by literature to be important risk factors for HPV progression, 
predictors which did not yield statistically significant association were also included in 
the final model based on epidemiologic considerations even though the final model was 
not the most parsimonious. Models by default included age at baseline. Interaction terms 
were used to assess effect modification by each of the variables included in the final 
multivariable model.  
 
Sensitivity analysis  
Sensitivity analyses were performed with (i) inclusion or exclusion of visit pairs that 
were more than 8 months apart., (ii) inclusion or exclusion of categories of days between 
visits in multivariable model.  







Five-hundred and thirty pre- and perimenopausal women were followed for HPV 
detection. Three hundred and eighty-three (72.3%) had at least 6-month follow-up at the 
time of analysis (Appendix. Appendix Table 4.1). The population that was included in 
analysis was not significantly different from the population at enrollment with regard to 
baseline hormonal contraceptive use, demographic characteristics, sexual behavioral 
factors, history of abnormal Pap smears and other sexually transmitted infection 
(Appendix. Appendix Table 4.1). The analysis population contributed a total of 928 visit 
pairs (Table 4.1), with a median follow-up time of 19.1 months (interquartile range (IQR) 
of 7.3 months). The median time between consecutive visits was 6.4 months (IQR: 2.4 
months). Eighty-three (8.9%) visit pairs were more than 1 year apart. Two-hundred and 
six visit-pairs were more than 8 months apart (25.8%).  
 
Analysis of incident HPV detection  
A total of 41 women had new HPV types detected. Seventy new cases of any HPV and 
twenty-nine incident cases of HR-HPV were detected during follow-up. The most 
common incident HR-HPV types were HPV type 16 (n=5, 17.2%) and 58 (n=4, 13.8%) 
(Figure 4.1). Women having new detection of HPV were more likely to be single 
(P<0.001), having sex with new partners in the past 6 months (P<0.001), or having more 
than 5 lifetime sex partners at baseline (P<0.001)(Table 4.1). These characteristics 
remained independent risk factors for HPV incident detection in multivariable analysis 






Women who reported current use of POCs were more likely to have incident HR-HPV 
(P=0.02)(Table 4.2). A greater proportion of current POC users had new detection of any 
HPV (11.4%) than never POC users (7.4%) though the estimate did not reach statistical 
significance (Table 4.2). In multivariable analysis, current use of POCs was found to 
associate with 3-fold increased risk of incident HR-HPV [adjusted odds ratio (aOR):  
3.24 (95% CI: 1.37-7.65)] after controlling for last menstrual period, acquisition of new 
sex partner since last visit, marital status since last visit, history of other sexually 
transmitted diseases since last visit, time between visits, number of lifetime sex partners 
at baseline, time since last abnormal pap smear at baseline (Table 4.4). Relative to never 
users, current use of POCs was also associated with higher odds of new detection of any 
HPV with borderline statistical significance [aOR: 1.64 (95% CI: 0.85-3.19)] (Table 4.4). 
Past use of POCs was not noted in our analysis to associate with incident detection of any 
HPV or HR-HPV. No significant association was seen between new detection of HPV 
and recency or duration of use of any hormonal contraceptives or OCs (Tables 4.5-4.7).  
Similar observations were observed with inclusion or exclusion of visit pairs that were 
more than 8 months apart in the analysis population as well as inclusion and exclusion of 
categories of days between screening visits in the multivariable model (results not shown).  
 
Secondary analysis of persistent HPV detection 
A secondary analysis of persistent HPV infection at 6-month follow-up was also done. 
Among women who had at least 6-month follow-up (n=383, 72.3%), 110 (61%) of HPV 
cases had persistent detection at the next follow-up visit (Appendix. Appendix Table 4.2). 




recency or duration of use of hormonal contraceptives, POCs or OCs, or other population 
characteristics (Appendix. Appendix Table 4.3). The results remained robust when visit 
pairs that were more than 8 months apart were excluded from the analysis population 
(results not shown).  
 
DISCUSSION 
We have previously reported that more than 5 years’ use of POCs was associated with 3-
fold increased prevalence of any HPV, and current use of POCs was found to associate 
with increased HPV prevalence with the estimate bordering on statistical significance. 
HPV prevalence is mediated by both the incidence and persistence of infection.  Our 
analyses on short-term prospective data revealed that current POC use was potentially 
linked to increased incident HPV detection. No significant positive association was 
detected between oral contraceptive (OC) use and HPV prevalent or incident detection in 
our study population.  
The majority of OCs belong to the category of COCs (18, 19). Association between COC 
and HPV prevalence was noted in younger female populations (10, 21-27). It has been 
proposed that the association between COC and HPV infection is mainly driven by 
COC’s effect on HPV persistence and not on acquisition (28). A previous study reported 
that prevalent carcinogenic HPV infections persisted more often in women aged ≥ 42 
years than in younger women, and persistent prevalent infections were associated with 
most of the CIN 2 or CIN3 lesions diagnosed in those females in that study (29). In our 
analysis on short-term follow-up, no significant difference in proportions of persistent 




hormonal contraceptive use. Perimenopausal women in our study were recruited from 
those who were routinely screened with Pap smears at gynecologic clinics and had been 
cytologically normal at baseline and during follow-up. It is possible that, should long-
term COC or other hormonal contraceptive use lead to persistent HPV infection which 
progresses into CIN lesion, these lesions would have been detected and treated in women 
during screening prior to study entry, hence resulting in the apparent lack of OC-
associated persistent prevalent HPV detection seen in our study. It is worthy to note that 
likelihood of persistence among newly detected HPV cases in women has not been 
shown to increase by age (29). This finding suggests that, in older women, increased 
HPV prevalence is not likely to be explained by increased persistence of new HPV 
detection.   
 
A positive association was observed between current POC use and HPV incident 
detection in our population. POCs, particularly DMPA, has been reported in other 
epidemiologic studies to associate with HIV acquisition in women (30, 32), although the 
finding has not been consistently reported across studies due to different study designs 
and population characteristics (33, 34).   
Progestin has been postulated to promote viral detection by causing cervical or vaginal 
changes that increase viral detectability. Natural progesterone during the luteal phase of 
menstrual cycle was found to reduce vaginal thickness (35, 36). High concentrations of 
progesterone in the luteal phase were linked to increased susceptibility to simian 
immunodeficiency viral infection in Pigtail macaques (37).The effect of synthetic 




Miller et al observed that short-term (6 months) use of DMPA led to lowered serum 
estradiol (35) as seen in other studies (38, 39), as well as changes in the vagina including 
a statistical significant though small decrease in cell layers associated with reduction of 
H2O2-positive Lactobacillus and vaginal glycogen. Others failed to detect such vaginal 
thinning effect with 1 single injection of DMPA (38), or with long-term (2-3 years) of 
DMPA use in case-control study (39).  These studies, however, were done in 
premenopausal women, and data on the effect of DMPA or POC on endocervical or 
vaginal epithelium in perimenopausal women are lacking. Atrophic vaginitis is a 
common ailment in late perimenopausal and early menopausal women. Perimenopause is 
characterized by a mix of ovulatory and anovulatory cycles accompanied by irregularities 
of endogenous estrogen (40). The hypoestrogenic effect of progesterone is likely 
augmented when endogenous estrogen drops to low levels, thereby creating a “window of 
vulnerability” in which short-term vaginal changes can occur, which in turn may perturb 
the epithelial barrier to HPV infection, and facilitate seeding/shedding of viral particles 
at/from the basal layer of the vaginal epithelium. In contrast to DMPA, COC use had not 
been found to affect the gross, colposcopic, or histologic appearance of the vaginal 
epithelium or characteristics of vaginal or cervical discharge (41). 
 
Sex hormones have been shown to influence immune responses in the female genital tract 
(42-45). Hormonal changes or imbalance can suppress host immune responses which in 
turn may induce reactivation of a latent virus. Alternatively, immunosuppression can 
impair clearing of a newly acquired or reactivated infection between screening visits, 




studies to have a general suppressive effect of on mucosal immunity. In vitro studies 
showed that progesterone, at pregnancy concentrations, can lead to increased production 
of IL4 and IL5 and reduced regulatory T cell function (46, 47). Exposure of HPV16 
VLP-stimulated PBMCs to estradiol and progesterone, either alone or in combination, 
was shown to significantly decrease the levels of lymphoproliferation and production of 
proinflammatory cytokines (48). In mouse models of herpes simplex 2 (HSV2)  infection, 
DMPA administration  led to significant lowering of local HSV2-specific 
immunoglobulin G (IgG) and IgA in their vaginal washes (49), resulting in dramatic 
increased susceptibility to HSV2 infection. Given the immunosuppressive effects of POC, 
it is reasonable to infer that POC may impair clearing of human HPV detection.  A 
previous study on younger women reported a mildly positive association (OR51.15; 95% 
CI: 1.01–1.32) between current use of injectable contraceptive and persistent HPV 
detection among those with mild or abnormal cytology (50), although the association was 
not consistently reported in others (51).   
 
Our study was an analysis of short-term follow-up data and was therefore limited in 
power to study the association between duration of POC use and HPV incidence or 
persistence. In addition, we were limited on self-report for information on sexual risk 
behaviors, making the observed associations subject to potential unmeasured and residual 
confounding.  Our study population reported low level of new sex exposure prior to 
baseline (2.8%) and during follow-up (3.3%). The confounding effect of unmeasured 
sexual behavior on the associations assessed would therefore likely be small when 





In summary, our analyses showed that current use of POCs was potentially associated 
with increased risk of incident HPV detection in short-term follow-up among women 
over the age of 35 years.  Such association had not been reported between HPV incidence 
and COC or POC in younger female population (28, 51-56). This contrast suggests that 
the nature of incident HPV detection in younger and older females may not be the same. 
Incident HPV detection can theoretically represent either a newly acquired infection, or 
detection of a previously acquired infection that has “re-emerged” from latency (13).  In a 
sexually active younger female population, more of the incident HPV detections are 
likely newly acquired infections. Older women, however, tend to have more stable sexual 
relationships (57), and incident detection may possibly represent a mixed pool of cases 
with higher proportion of viral reactivation instead of just newly acquired infection. 
Long-term follow-up data focused on older women will allow us to better assess the 
longitudinal relationship between HC use and HPV incidence and persistence. Further 
studies are also warranted to evaluate the biologic impact of POC and other hormonal 
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TABLES AND FIGURE 
Table 4.1. Characteristics of study population and incident  HPV detection during follow-up  (Total number of visit pairs: 928) 
 
Characteristics at follow-up visit 
 




Incident detection of 
any HPV since last visit 





 Incident detection of any 






Demographic characteristics        
Age at enrollment years)    0.75   0.85 
35-39  244 (26.3) 16 (6.6)   8 (3.3)  
40-44  249 (26.8) 20 (8.0)   9 (.3.6)  
45-49  305 (32.9) 26 (8.5)   10 (3.3)  
≥50  123 (13.3) 8 (6.2)   2 (1.6)  
        
Race at enrollment    0.34   0.75 
Caucasian  713 (76.8) 52 (7.3)   23 (3.2)  
African American  150 (16.2) 15 (10.0)   5 (3.33)  
Others c  65 (7.0) 3 (4.6)   1 (1.5)  
        
Marital status since last visit    <0.001   0.01 
Married  616 (66.4) 26 (4.2)   13 (2.1)  
Single  169 (18.2) 19 (11.2)   6 (3.6)  
Divorced/separated/widowed  143 (15.4) 25 (17.5)   10 (7.0)  
        
Smoked since last visit    0.12   0.63 
No  854 (92.0) 61 (7.1)   26 (3.0)  
Yes  74 (8.0) 9 (12.2)   3 (4.1)  
        
Parity at enrollment    0.19   0.22 
0 or 1  302 (32.6) 27 (8.9)   11 (3.6)  
2  197 (21.3) 18 (9.1)   9 (4.6)  
>2  427 (46.1) 25 (5.9)   9 (2.1)  
        
Sexual behavioral characteristics        
Frequency of sex since last visit (times/month)    0.09   0.29 
None  72 (7.8) 8 (11.1)   3 (4.2)  
1-2  163 (17.6) 14 (8.6)   6 (3.7)  
3-4  198 (21.3) 7 (3.5)   2 (1.0)  
≥5  495 (53.3) 41 (8.3)   18 (3.6)  
        




No sex  150 (16.2) 12 (8.0)   5 (3.3)  
Have sex but no new sexual partner  747 (80.5) 49 (6.6)   21 (2.8)  
Have sex with new sexual partner  31 (3.3) 9 (29.0)   3 (9.7)  
        
Lifetime number of sexual partners    <0.001   0.001 
<5  375 (40.4) 9 (2.4)   2 (0.5)  
5-10  352 (37.9) 40 (11.4)   18 (5.1)  
>10  201 (21.7) 21 (10.5)   9 (4.5)  
        
Last menstrual period (days)    0.67   0.25 
1-14  410 (44.2) 34 (8.3)   15 (3.7)  
15-28  332 (35.8) 23 (6.9)   8 (2.4)  
28-40  62 (6.7) 6 (9.7)   4 (6.5)  
40-365  124 (13.4) 7 (5.7)   2 (1.6)  
        
Ever had colposcopy    0.56   0.21 
No  732 (78.9) 53 (7.3)   20 (2.8)  
Yes  197 (21.2) 17 (8.5)   9 (4.5)  
        
Ever had treatment for abnormal pap smear    0.34   0.31 
No  768 (82.8) 55 (7.2)   22 (2.9)  
Yes  160 (17.2) 15 (9.4)   7 (4.4)  
Time since last abnormal pap smear    0.05   0.03 
Never had abnormal pap smear  521 (56.1) 30 (5.8)   9 (1.7)  
<1 year ago  29 (3.1) 3 (10.3)   1 (3.5)  
2-5 years ago  89 (9.6) 12 (13.5)   6 (6.7)  
≥6 years ago  289 (31.1) 25 (8.7)   13 (4.5)  
        
Diagnosed with other sexually transmitted 
infections  in the past 6 months d 
    
0.62 
 
   
0.06 
No  909 (98.0) 68 (7,.5)   27 (3.0)  
Yes 
 
 19 (2.1) 2 (10.5)   2 (10.5)  
a. Percentages or numbers in categories may not add up to 100% or the total number due to missing data.  
b. HR-HPV types: oncogenic HPV as defined as types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 (IARC 2007). 
c. Other categories include American Indian (n=2), Pacific Islander (n=2), Asian (n=16), unidentified (n=9).  





Table 4.2. Hormonal contraceptive use and new HPV detection in study population (Total number of visit pairs: 928) 
 
Characteristics at current follow-up visit 
 




Incident detection of any 
HPV since last visit 





Incident detection of any  





















Duration of use Years      
 Never used any HC  91 (9.8) 5 (5.5)  2 (2.2)  
Current  ≤5 365 (39.3) 26 (7.1)  13 (3.6)  
 >5  41 (4.4) 5 (12.2)  1 (2.4  
Former ≤5 151 (16.3) 10 (6.6)  3 (2.0)  
 >5  253 (27.3) 22 (8.7)  9 (3.6)  
Unclear duration  27 (2.9) 2 (7.4)  1 (3.7)  
       
Time since last use at last visit    0.38  0.73 
 Never user   91 (9.8) 5 (5.5)  2 (2.2)  
Current user   202 (21.8) 18 (8.9)  8 (4.0)  
Last use ≤ 5 years ago  194 (20.9) 13 (6.7)  8 (4.1)  
Last use  6-10 years ago  104 (11.2) 4 (3.9)  3 (2.9)  
Last use >10 years ago  337 (36.3) 30 (8.9)  8 (2.4)  
       
 
Use of any progestin-only contraceptives 
 













 Never used any progestin-only 
contraceptives 
 691 (74.5) 48 (7.0)  17 (2.5)  
Ever users  ≤5 208 (22.4) 19 (9.1)  10 (4.8)  
 >5  26 (2.8) 2 (7.7)  2 (7.7)  
Cannot be determined  3 (0.3) 1 (33.3)  0 (0)  
       
Time since last use at last visit     0.27  0.02 
 Never used any progestin-only 
contraceptives 
 691 (74.5) 48 (7.0)  17 (2.5)  
Current user   105 (11.3) 12 (11.4)  8 (7.6)  
Past user   132 (14.2) 10 (7.6)  4 (3.0)  





Use of oral contraceptives 
 













 Never used any oral contraceptives  164 (17.7) 15 (9.2)  4 (2.4)  
Ever users  ≤5 380 (41.0) 23 (6.1)  11 (2.9)  
 >5  338 (36.4) 30 (8.9)  12  (3.6)  
Cannot be determined  46 (5.0) 2 (4.4)  2 (4.4)  
       
Time since last use    0.66  0.13 
 Never used any oral contraceptives  164 (17.7) 15 (9.2)  4 (2.4)  
Current user   93 (10.2) 6 (6.5)  0 (0)  
Past user  671 (72.3) 49 (7.3)  25 (3.7)  





Table 4.3. Association between any hormonal contraceptive use and new HPV detection during follow-up (Total number of visit 
pairs: 928) 
 
Characteristics at current follow-up 
visit 
Total visit pairs 
N=928  
 Incident detection of  any HPV 
n=70 (7.5%) 






















 (95% CI) 
 
Use of any hormonal contraceptives 
Last time of use 
         
 Never user          91 (9.8)  5 (5.5) Ref Ref  2 (2.2) Ref Ref 
Current user          202 (21.8)  18 (8.9) 1.81 (0.68-4.79) 1.23 (0.39-3.86)  8 (4.0) 1.88 (0.40-8.76) 0.97 (0.18-5.06) 
Past user         635 (68.4)  47 (7.4) 1.47 (0.59-3.67) 1.05 (0.35-3.15)  19 (3.0) 1.44 (0.34-6.14) 0.76 (0.15-3.94) 
           
Time from last menstrual period               
Days 
          
1-14  410 (44.2)  34 (8.3) Ref Ref  15 (3.7) Ref Ref 
15-28  332 (35.8)  23 (6.9) 0.83 (0.47-1.46) 1.17 (0.63-2.18)  8 (2.4) 0.66 (0.26-1.70) 1.20 (0.46-3.08) 
28-40  62 (6.7)  6 (9.7) 0.60 (0.24-1.53) 0.40 (0.09-1.78)  4 (6.5) 1.92 90.64-5.76) 0.48 (0.06-3.94) 
40-365  124 (13.4)  7 (5.7) 1.24 (0.52-2.99) 1.32 (0.60-2.92)  2 (1.6) 0.43 (0.10-1.82) 0.80 (0.23-2.81) 
           
Lifetime number of sexual partners           
<5  125 (13.5)  9 (2.4) Ref Ref  2 (0.5) Ref Ref 
6-10  250 (26.9)  40 (11.4) 4.81 (2.20-10.54) 4.32 (2.01-9.29)  18 (5.1) 9.39 (2.19-40.29) 7.89 (1.86-33.50) 
>10  553 (59.6)  21 (10.5) 4.33 (1.86-10.10) 3.01 (1.23-7.38)  9 (4.5) 8.17 (1.74-38.31) 5.38 (1.11-26.04) 
           
Sexual activity in last 6 months           
No sex  150 (16.2)  12 (8.0) Ref Ref  5 (3.3) Ref Ref 
Have sex but no new sexual 
partner 
 747 (80.5)  49 (6.6) 0.80 (0.42-1.51) 1.45 (0.66-3.18)  21 (2.8) 0.84 (0.32-2.23) 1.07 (0.35-3.24) 
Have sex with new sexual 
partner 
 31 (3.3)  9 (29.0) 4.22 (1.55-11.49) 3.60 (1.25-10.36)  3 (9.7) 3.00 (0.67-13.41) 2.70 (0.61-11.91) 
           
Marital status           
Married  616 (66.4)  26 (4.2) Ref Ref  13 (2.1) Ref Ref 
Single  169 (18.2)  19 (11.2) 2.97 (1.55-5.74) 2.73 (1.28-5.84)  6 (3.6) 1.64 (0.55-4.90) 1.29 (0.35-4.75) 
Divorced/separated/widowed  143 (15.4)  25 (17.5) 4.84 (2.60-9.00) 3.45 (1.72-6.90)  10 (7.0) 3.30 (1.37-7.90) 2.32 (0.89-6.00) 
           




Time since last abnormal pap smear 
Never  521 (56.1)  30 (5.8) Ref Ref  9 (1.7) Ref Ref 
< 1 year ago  29 (3.1)  3 (10.3) 1.94 (0.61-6.13) 2.17 (0.73-6.44)  1 (3.5) 2.01 (0.28-14.45) 2.01 (0.35-11.65) 
2-5 years ago  89 (9.6)  12 (13.5) 2.61 (1.24-5.49) 1.74 (0.78-3.85)  6 (6.7) 4.13 (1.48-11.57) 3.56 (1.15-11.06) 
≥ 6 years ago  289 (31.1)  25 (8.7) 1.55 (0.85-2.82) 1.22 (0.66-2.26)  13 (4.5) 2.68 (1.10-6.54) 2.19 (0.90-5.36) 
           
a Adjusted for days from last menstrual period, acquisition of new sex partner since last visit, marital status since last visit,  time since last abnormal pap smear at baseline, number of lifetime 







Table 4.4. Association between new HPV detection and recency of any progestin-only hormonal contraceptive use (Total number 
of visit pairs: 928) 




Incident detection of any HPV 
n=70 (7.5%) 
 
Incident detection of HR-HPV 
n=29 (3.1%) 




















 (95% CI) 
 
Use of progestin-only contraceptives 
          
           
Last time of use           
 Never user  691 (74.5)  48 (7.0) Ref Ref  17 (2.5) Ref Ref 
Current user   105 (11.3)  12 (11.4) 1.77 (0.94-3.34) 1.64 (0.85-3.19)  8 (7.6) 3.22 (1.39-7.44) 3.24 (1.37-7.65) 
Past user  132 (14.2)  10 (7.6) 1.06 (0.49-2.28) 1.15 (0.48-2.75)  4 (3.0) 1.22 (0.41-3.62) 1.32 (0.42-4.09) 
           
a Adjusted for days from last menstrual period, acquisition of new sex partner since last visit, marital status since last visit,  time since last abnormal pap smear at baseline, number of 







Table 4.5. Association between new HPV detection and recency of oral contraceptive use (Total number of visit pairs: 928) 




Incident detection of any HPV 
n=70 (7.5%) 
 
Incident detection of HR-HPV 
n=29 (3.1%) 




















 (95% CI) 
 
Use of oral contraceptives 
          
           
Last time of use           
 Never user  164 (17.7)  15 (9.2) Ref Ref  4 (2.4) Ref Ref 
Current user   93 (10.2)  6 (6.5) 0.64 (0.24-1.71) 0.57 (0.20-1.64)  0 (0) na na 
Past user  671 (72.3)  49 (7.3) 0.81 (0.43-1.51) 0.63 (0.30-1.33)  25 (3.7) na na 
           
a Adjusted for days from last menstrual period, acquisition of new sex partner since last visit, marital status since last visit,  time since last abnormal pap smear at baseline, number of 
lifetime sex partners at baseline. 



















Incident detection of any HPV 
n=70 (7.5%) 
 






















 (95% CI) 
 
Use of any hormonal 
contraceptives 
          
 
   Duration of most recent use 
 
Years 
         
Never user  91 (9.8)  5 (5.5) Ref Ref  2 (2.2) Ref Ref 
Ever user           
 ≤5  516 (55.6)  36 (7.0) 1.45 (0.57-3.69) 0.92 (0.30-2.82)  16 (3.1) 1.57 (0.37-6.75) 0.76 (0.15-3.82) 
 >5 294 (31.7)  27 (9.2) 1.72 (0.66-4.45) 1.49 (0.48-4.62)  10 (3.4) 1.51 (0.32-7.15) 0.91 (0.16-5.07) 
Cannot be determined  27 (2.9)  2 (7.4) 1.26 (0.26-6.21) 0.96 (0.15-5.03)  1 (3.7) 1.55 (0.14-17.4) 0.88 (0.06-13.83) 
           
a Adjusted for days from last menstrual period, acquisition of new sex partner since last visit, marital status since last visit,  time since last abnormal pap smear at baseline, number of 









Table 4.7. Association between new HPV detection and duration of oral contraceptive use (Total number of visit pairs: 928) 
 
 







Incident detection of any HPV 
n=70 (7.5%) 
 






















 (95% CI) 
 
Use of oral contraceptives 
          
 
   Duration of most recent use 
 
Years 
         
Never user   164 (17.7)  15 (9.2) Ref Ref  4 (2.4) Ref Ref 
Ever user           
 ≤5  380 (41.0)  23 (6.1) 0.66 (0.32-1.35) 0.47 (0.20-1.08)  11 (2.9) 1.22 (0.39-3.75) 0.78 (0.24-2.48) 
 >5 338 (36.4)  30 (8.9) 0.97 (0.50-1.89) 0.89 (0.40-1.98)  12  (3.6) 1.45 (0.46-4.61) 1.10 (0.32-3.73) 
Cannot be determined  46 (5.0)  2 (4.4) 0.45 (0.11-1.93) 0.36 (0.08-1.65)  2 (4.4) 1.78 (0.34-9.26) 1.56 (0.26-9.22) 
           
a Adjusted for days from last menstrual period, acquisition of new sex partner since last visit, marital status since last visit,  time since last abnormal pap smear at baseline, number of 
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Long-term and recent use of combined oral contraceptives was suggested to associate 
with increased risk of cervical cancer. Study findings on the association between 
hormonal contraceptive use and HPV infection have been inconsistent. Most data were 
drawn from women aged below 35 years. Little is known about the effect of hormonal 
contraceptive use on host cervical immune milieu and HPV detection in older women.   
 
Objective: 
The aim of this study was to compare the host cervical cytokine profiles between current 
and non-current hormonal contraceptive users among HPV-negative women who were 
aged over 35 years.   
 
Methods: 
Pre- and perimenopausal women (aged 35-54 years) were recruited from gynecologic 
clinics in Baltimore, Maryland. Pairs of cervical secretion samples were collected from 
105 current hormonal contraceptive users and 105 non-current users who were 
matched on 5-year age groups. Subjects tested were (i) HPV-negative at baseline, (ii) 
did not have other recent genital infections or abnormal Pap smears, (iii) did not report 
use exogenous sex hormones other than hormonal contraceptives in the past 6 months. 
Extracted specimens from cervical secretion samples were tested by a polystyrene bead-
based multiplex assay for 27 immune markers (cytokines, chemokines and growth 




milligrams of protein to correct for sampling variability. Comparison of individual mean 
cytokine levels were made using paired-t-test between user groups of hormonal 
contraceptives. Collective comparison was done using Spearman’s rank correlation 
coefficients to determine correlations for all pairwise combinations of the 27 cytokines, 
chemokines, and growth factors measured. Differences between correlation coefficients 




Cytokine correlation patterns differed between current and non-current hormonal 
contraceptive users. In non-current users, there were significantly more positive 
correlations detected among proinflammatory cytokines, most notably IP10, MCP1, 
MIP1a and RANTES, as well as between proinflammatory and immunoregulatory 
cytokines. Overall cytokine correlations were weaker among current hormonal 
contraceptive users than non-current users.  
Relative to non-current hormonal contraceptive users, current progestin-only 
contraceptive (POC) users were found to have statistically significantly lower levels of 
IP10, IL-12, IL-13, IL-15, while current combined oral contraceptive (COC) users had 
significantly lower levels of IL-2, IP10 and MCP1. Compared to COC users, POC users 
appeared to show fewer significant correlations among immunoregulatory cytokines, as 
well as a suggestion of a more predominant Th2-skewed profile as evidenced by 
significant correlations between IL-4, IL-10, and IL-13. The findings suggested 






Our analyses revealed differences in cytokine profiles between current and non-current 
hormonal contraceptive users in HPV-negative women. Correlation analyses of cytokine 
measurements hinted at effects of hormonal contraceptive use on coordinated immune 






Cervical cancer is the third most common gynecologic cancer in women in the U.S. (1). 
Uncontrolled persistent infection with a high-risk type human papillomavirus (HPV) has 
been postulated to be an essential but not sufficient cause for cervical dysplasia and 
neoplasia (2). The risk of HPV persistence is significantly higher among 
immunosuppressed patients (3-6). Other host exposure factors, such as use of hormonal 
contraceptives and smoking, were observed to increase the risk of persistent HPV 
infection and cervical cancer (7-10), suggesting that interaction of viral factors, local  
immunity and hormonal status underlies the detection, progression and carcinogenesis of 
HPV infection (11). 
Both the innate and cellular immune systems are important determinants for clearance of 
cervical HPV infection (12-14).   Epithelial cells lining the cervicovaginal mucosa are 
able to express cytokines, sex hormone receptors and genital tract-specific defensins (15-
16), and hence are vital components in mucosal innate and adaptive immunity (17). 
Cytokines are constitutively expressed by the cervicovaginal cells at low levels in a para- 
and autocrine fashion (18), and are also secreted by immune effector cells during immune 
activation. Cytokines can generally be classified into a number of categories according to 
the nature of their actions on the immune system (19, 20): (i) “proinflammatory” 
cytokines that contribute to the inflammatory process by activating leucocytes, e.g. IL-1, 
TNF-α, RANTES, (ii) Immunoregulatory/proinflammatory cytokines that stimulate 
inflammation and cell-mediated responses (Th1), e.g. IL-2, IL-12, IFN-γ, (iii) 
Immunoregulatory/anti-inflammatory cytokines that mediate humoral immunity as well 




associated cytokines, such as IL-17 and IL-22 (18),   (v) growth factors, such as GCSF, 
GMCSF, VEGF (19-20). A local Th1 response has been observed in women who cleared 
HPV infection (21), while Th2 response cytokines were found to be increased in HIV-
positive HPV-co-infected persons compared to those infected with HPV alone or not 
infected (22-24). These findings indicated that a shift from Th1 to Th2 response might 
contribute to HPV persistence. 
A number of past studies on immunity to HPV were limited in using serum cytokine 
levels as surrogate markers for cervical immunity (reviewed in 25), while in reality serum 
and cervical cytokine concentrations are not well correlated (12). This lack of correlation 
was observed similarly in women with recent HPV infection, hinting that HPV infection 
may not cause gross changes in epithelial permeability that result in serum transudation 
of cytokines (12). Factors influencing local mucosal immunity against viral infection are 
still not fully elucidated. Use of oral contraceptives has been shown in observational 
studies to correlate with elevated cervical IL-10 and IL-12 levels (26, 27).  A previous 
study showed that treatment of peripheral blood mononuclear cells in vitro with 
biologically relevant concentrations of estrogen and progesterone led to suppressed 
expression of proinflammatory cytokines  and increased expression of anti-inflammatory 
cytokines in response to HPV16 virus-like particle exposure (28). Most of the previous 
studies on cervical immune milieu, however, are focused on young women, and baseline 
data in older women have been lacking. 
We have previously shown that long-term use of progestin-only contraceptives (POCs) is 
associated with 3-fold increase in HPV prevalence and current use of POCs is potentially 




perimenopausal females over the age of 35 years. In this study, we sought to investigate 
the baseline cervical cytokine milieu of current versus non-current hormonal 
contraceptive users to see if the differences correlate with our epidemiologic observations 
in this population.   
 
Materials and Methods 
Study design 
Baseline cervical secretion samples were taken from women enrolled in an observational 
prospective study assessing the natural history of HPV during the perimenopausal 
transition. Briefly, women aged 35 to 60 years were recruited from gynecological clinics 
associated with the Johns Hopkins Medical Institutions in Baltimore, MD. Exclusion 
criteria for the parent study included the following: (i) history of hysterectomy, organ 
transplant or HIV infection, (ii) currently pregnant, (iii) unable to provide informed 
consent, (iv) unwilling to provide contact information, (v) non-English speaking. The 
study protocols were reviewed and approved by the Institutional Review Board at Johns 
Hopkins Bloomberg School of Public Health, Baltimore, MD.  
Standardized questionnaires were administered by trained interviewers at baseline and 
follow-up visits. Information was collected on (i) use of hormonal contraceptives 
including duration of use, time since last use, indications of use and brand names, (ii) 
demographic information, (iii) sexual behavioral characteristics, (iv) reproductive history, 
(v) smoking history, (vi) use of medications other than hormonal contraceptives, (vii) 






HPV DNA type-specific testing was done on cervical swab samples.  DNA was extracted 
using the QIAamp DNA Blood Kit (Qiagen, Courtaboeuf, France) according to 
manufacturer’s instructions with modification.  After extraction, 8 μls of DNA (4% of 
total volume of extracted DNA) was amplified using the PGMY09/11 L1 consensus 
primer system, which amplified with high efficiency over 40 HPV genotypes known to 
infect the genital tract. Genotype discrimination was performed by hybridizing 40 μl of 
the PCR product to a membrane with immobilized probes targeting 37 HPV genotypes 
(HPV Linear Array Roche Molecular Systems, Roche Diagnostics, Indianapolis, IN).   
 
Sample collection  
Selection of samples for cytokine measurement  
Samples from current hormonal contraceptive users were selected from subjects who (i) 
were HPV-negative at baseline, (ii) currently used hormonal contraceptives in the past 1 
month, (iii) did not have abnormal Pap smears or genital infections in the past 6 months, 
(iv) did not currently use other exogenous sex hormones including hormone replacement 
therapy. Postmenopausal women were excluded from the study. Those who reported 
current hormonal contraceptive use but had last menstrual period more than 1 year ago 
were included in the selected samples (n=22) if (i) age <55 years, (ii) use of contraceptive 
(e.g. DMPA or Mirena) were related to cessation of periods, or (iii) use of HC was for 
“perimenopausal symptoms.” 
Samples from non-current hormonal contraceptive users were selected from those with 




Non-current hormonal contraceptive users were excluded from selection if (i) status of 
last hormonal contraceptive use was <5 years ago or was missing, (ii) last menstrual 
period was >1 year ago, (iii) did not have abnormal Pap smears or genital infections in 
the past 6 months, (iv) did not currently use other exogenous sex hormones including 
hormone replacement therapy. 
Current and non-current hormonal contraceptive users were randomly selected with 1:1 
match on the following characteristics (i) age in 5-year categories, and (ii) last menstrual 
period in categories of days (1-14; 15-28, 28-40, 40-365). Last menstrual period was 
matched in categories among user pairs, except for 11 pairs for which no exact match 
were found and the closest category was used for matching instead.  
  
Specimen processing and cytokine measurement 
Protein for cytokine analysis was extracted from the ophthalmic sponges using previously 
described methods (29). Briefly, sponges were thawed at room temperature for 10 min 
and then weighed. Sponges were then inserted into a microcentrifuge tube containing a 
0.2 lm filter (SpinX, Costar), equilibrated by adding 300 ul of extraction buffer (10 
mg/ml aprotinin in phosphate buffered saline with 10% sodium azide) and incubated for 
30 min at 4 
o
C, followed by centrifugation at 4
 o
C for 30 min at 14,000 rpm. After 
centrifugation, specimens were stored at 20 
o
C until the time of cytokine measurement. 
The following cytokines, chemokines, and growth factors were measured using a 
polystyrene non-magnetic bead-based multiplex assay according to the manufacturer’s 
protocol (Bio-Rad, Hercules, CA): TH1-related: IFN-γ, IL-2, IL-12, IL-15; TH2-related: 




cytokines and chemokines (eotaxin, IL-1β, IL-1rα, IL-6, IL-8, IP10, MCP1, MIP1α, 
MIP1β, RANTES, TNF-α), and growth factors (IL-7, G-CSF, GM-CSF, basic FGF, 
VEGF, PDGF- bb). Plates were read using a Luminex instrument (Bio-Rad, Hercules, 
CA). An eight point standard curve was created and fit using a five parameter logistic 
model. Specimens were tested across plates. Duplicates within plate and replicates across 
plates were tested to control for observed intra and inter-assay variability. 
In order to control for inter-individual variability in immune marker measured due to 
differences in the amount of specimen collected, the total concentration of protein was 
measured in each specimen using a bicinchoninic acid (BCA) assay per manufacturer’s 
protocol (Pierce, Rockford, IL). Specimens were diluted 1:10 and 1:100 in PBS and run 
in duplicate. Colorimetric detection of test specimens was normalized to background 
specimens that contain extraction buffer only. Total protein concentration was estimated 




Cytokine concentrations that were outside detection range were managed as previously 
described (29). Specifically, those values that were below the limit of detection and 
completely outside the dynamic range and reported as undetectable by the Luminex 
instrument were assigned ½ the lowest measured value in the sample. Cytokine 
concentrations that were below the manufacturer’s published limit of detection, but a 
concentration was estimated by the instrument from the standard curve, were assigned 




detection and completely outside the dynamic range were coded as unobserved values. 
Cytokine that has more than 25% of values outside detection range were not included in 
analyses for comparison between exposure groups.  
 
Comparison of cytokine measurements among hormonal contraceptive user groups 
Protein-adjusted cytokine measurements were normalized by log transformation. 
Comparison of log-transformed levels of individual cytokines was made between 
matched pairs of current and non-current hormonal contraceptive users at baseline using 
paired t-test.  Global comparison of cytokine measurements was made my assessing 
correlations between all pairwise combinations of cytokine measurements that were 
within detection limits.  Spearman’s rho, a non-parametric alternative to the correlation 
coefficient r, was used to calculate correlations. P values were adjusted by Sidak 
correction for multiple comparisons. Differences between correlation coefficients were 
tested by z-test of the Fisher’s r to z-transformation of the Spearman rho correlation 
coefficient as previously published (30, 31). 
 
Sensitivity analysis  
Sensitivity analysis was performed with inclusion and exclusion of values that were 
either completely undetectable or outside the dynamic range of the assay. The observed 








Population characteristics  
A total of 105 pairs of samples from current and non-current hormonal contraceptive 
users matched in 5-year age groups were assessed. Mean ages of current and non-current 
hormonal contraceptive users were 42.4 (SD: 4.7 years) and 43.1 (SD: 4.7 years) years 
respectively. Most of the samples came from premenopausal women (75%). A majority 
of the tested population either never had abnormal Pap smear (58.6%) or had abnormal 
test result more than 1 year ago (39.5%). No significant difference was seen between 
current and non-current hormonal contraceptive users in terms of lifetime number of 
sexual partners, sexual activity in the past 6 months, history of colposcopy, marital status, 
parity or race (Table 5.1). Among current hormonal contraceptive users, 39% reported 
current use of combined oral contraceptives (COCs) and 47% had current use of 
progestin-only contraceptives (POCs) (Appendix. Appendix Table 5.2). 
 
Cytokine measurements by hormonal contraceptive use 
There was no difference between current and non-current hormonal contraceptive users 
in proportion of samples having values outside detection limits. Of the 27 cytokine 
markers measured, 4 had more than 25% of samples yielding values outside detection 
range, which included eotaxin, IL-8, IL-1ra, IL-5. Thus measurements of these 4 markers 
were not interpreted in comparison studies (Appendix. Appendix Table 5.1).  
Levels of cytokines were not significantly different between current and non-current 
hormonal contraceptive users for the majority of markers assessed, except IP10 and IL1b 




users had lower levels of IP10 (mean: 818.4 pg cytokine/mg protein; SD: 958.6 pg 
cytokine/mg protein) as compared to non-current users (mean: 1591.7 pg cytokine/mg 
protein; SD: 2302.2 pg cytokine/mg protein) (P=0.03). Slightly lower level of IL1b was 
observed among non-current users (mean: 81.9 pg cytokine/mg protein; SD: 111.8 pg 
cytokine/mg protein) than current users (mean: 95.8 pg cytokine/mg protein; SD: 158.4 
pg cytokine/mg protein)(P=0.04) (Table 5.2).  
Relative to non-current hormonal contraceptive matched subjects, current COC users had 
significantly lower levels of IL2 (P=0.02), IP10 (P=0.002) and MCP1 (P=0.01). In 
contrast, current POC users had higher level of IL1b (P=0.01), and lower levels of IL12 
(P=0.03), IL13 (P=0.048), IL15 (P=0.048), as well as IP10 (P=0.02) than non-current 
hormonal contraceptive matched users (Table 5.3).  
 
Correlations of cytokine measurements by hormonal contraceptive use 
Significant positive correlations were observed among both current and non-current 
hormonal contraceptive users among immunoregulatory cytokines, including INF-γ, IL-2, 
IL-12, IL-4, IL-9, IL-10, IL-13, IL-15, IL-17, IL-7. However, among non-current users, 
significantly more proinflammatory cytokines were involved in positive correlations with 
immunoregulatory cytokines. IP10 was significantly more positively correlated with INF-
γ, IL-12, IL-4, IL-9, IL-10, IL-13, IL-15, IL-17, in non-current users but not in current 
users. MCP1 was statistically significantly positively correlated with INF-γ, IL-2, IL-4, 
IL-15, IL-17, IL-7 in non-current users but such correlations were not observed in current 
users. Similarly, RANTES was statistically significantly correlated with INF-γ, IL-12, IL-




(Figure 5.1, Figure 5.2, Figure 5.3). The coefficients for the correlations noted above for 
IP10, MCP1 and RANTES were statistically significantly more negative (lower in 
magnitude) in current hormonal contraceptive users than non-current users (Figure 5.4). 
Correlations were also in general more negative (lower in magnitude) among other 
proinflammatory and immunoregulatory cytokines in current hormonal contraceptive 
users (Figure 5.4).  
Correlations of cytokines among current COC and POC users involved mostly 
immunoregulatory cytokines. More significant correlations were observed among IL-15, 
IL-17, IL-9, IL-10, IL-12, and INF-γ in current COC users and current POC users. POC 
users appeared to show fewer significant correlations among immunoregulatory 
cytokines, as well as a suggestion of a more predominant Th2-skewed profile as 
evidenced by significant correlations between IL-4, IL-10, and IL-13 (Figure 5.5, Figure 
5.6, Figure 5.7). 
 Compared to COC users, correlations were significantly weaker among 
immunoregulatory cytokines such as IL-9, IL-15 and IL-17, as well as among IL-5, IL-15, 
IL-17 in current POC users (Figure 5.8).  
 
DISCUSSION  
Cytokines are essential in mediating innate and cellular adaptive immune responses 
against viral infections. Data on correlates of mucosal immunity, particularly cytokines, 
in female human genital tract are limited in older women. In this study, we provided data 




menstrual cycle, stratified on current use of hormonal contraceptives. Among healthy, 
HPV-negative women, while absolute levels of cytokines were not significantly 
associated with current use of any hormonal contraceptives, there was a significant lack 
of positive correlations among proinflammatory cytokines as well as between 
proinflammatory and immunoregulatory cytokines in current hormonal contraceptive 
users versus non-current users.  
The lack of association between absolute cytokine levels and hormonal contraceptives 
could be explained in two ways. It is known that in asymptomatic women, even among 
those harboring HPV infection, there is in general a lack of measurable inflammatory 
response (18, 24, 25). Should hormonal contraceptive use have an effect on cervical 
levels of cytokines, the difference may be too small to detect in a small-scale study 
among healthy women with no observed genital inflammation.  Furthermore cytokines 
are often produced by the same immune cell subsets or by cells that interact and regulate 
one another in a highly dynamic state, hence their biological levels and activities are 
context-specific (29, 32). Studies on individual levels of cytokines may therefore be 
subject to study variations in population characteristics, sampling techniques and analytic 
methodologies.  
 
The need to study cytokines as an integrated network in addition to their individual levels 
becomes apparent when we consider the current body of work on cervical cytokines in 
women in relation to HPV status and hormonal contraceptive use. For instance, previous 




status (25, 26, 29), while two other studies reported higher levels of IL-12 in HPV-
positive women relative to HPV-negative women (22, 25, 33). Lieberman et al suggested 
that IL-6 levels were reduced in women with incident HPV infections (32, reviewed in 
25), while another study found that IL-6 levels tended to be elevated in HPV-positive 
women (33, reviewed in 25). Similar inconsistencies were reported in previous studies on 
cervical cytokines and hormonal contraceptive use. For example, IL-10 and IL-12 had 
been noted to be elevated in adolescent and young adult women on oral contraceptives 
(26, 27), but a recent study (22) did not replicate the findings. These inconsistencies 
suggest that comparing absolute levels of individual cytokines do not fully capture the 
interaction of cytokines with host and viral factors in the female genital tract.  
Our study’s findings were unique in highlighting the effect of current hormonal 
contraceptive use on the correlative patterns of cervical cytokines. Fluctuations of 
endogenous estradiol and progesterone have long been observed to influence mucosal 
immunity in the lower genital tract. Timing of menstrual cycle phase is associated with 
the concentrations of cyto-/chemokines in cervicovaginal secretions (36). Wira et al 
found that ectocervical and vaginal secretions exhibit a pattern of innate immune 
protection that is physiologically suppressed at mid-menstrual cycle (37, 38). Estradiol 
(E2) and progesterone influence the migration of immune cells, such as macrophages, 
dendritic cells (DC) as well as T and B cells, by affecting the expression of adhesion 
molecules and chemotactic factors (13, 37-38). These immune cells then signal the 
recruitment and activation of other cells of the innate and adaptive immune systems by 
the production of cytokines and chemokines.  Exogenous sex hormones had also been 




ability of cervicovaginal lavage to inhibit HSV infection in vitro decreased significantly 
in oral contraceptive users compared with non-users (39, 40).  Progesterone has been 
observed to suppress cell-mediated immune responses in vitro, including inhibiting 
cytotoxic T cell activity, reducing NK T cell function, and skewing cytokine production 
towards a general Th2 response (reviewed in 40). Mice treated with DMPA exhibited 
decreased levels of HSV-2 specific mucosal immune responses after intravaginal 
immunization with TK-HSV2 (40, 41).  The effect of estrogen is more complicated, as 
the hormone can be either proinflammatory or anti-inflammatory depending on its 
concentrations (42). At high concentrations (>10
6
M), estrogen was shown to inhibit 
cellular immunity by impairing cytotoxic T cell activity(43, 44) and decreasing migration 
of T cells and macrophages into the genital tract by downregulating expression of 
adhesion molecules including ICAM-1, VCAM-1 and E-selectins (28, 42, 44). At low 
concentrations (<10
-8
M), estrogen induces TNF-α, IL-6 and IL-1β expression, inhibits 
Th2-type cytokines, and increases migration of leukocytes to the site of inflammation (28, 
40, 42).  
In our study, current hormonal contraceptive use was found to associate with 
significantly weaker positive correlations among proinflammatory cytokines, particularly 
IP10, MCP1, MIP1a and RANTES, as well as between proinflammatory and 
immunoregulatory cytokines that mediate Th1 and Th2 responses.  In addition, overall 
cytokine correlations were more negative (lower in magnitude) among current hormonal 
contraceptive users than non-current users. The finding suggests that when active HPV 
infection is absent, exogenous sex hormones may dysregulate the baseline cervical 




chemokines which are crucial in mediating innate and adaptive factors in mucosal 
immunity. It is known that the innate immune system, which serves as the first line of 
mucosal defense, is activated to create a pro-inflammatory microenvironment in the early 
stages of HPV infection (14). Immune cells are then recruited, initiating 
adaptive immune response. Clearance of HPV infection therefore relies on effective local 
Th1 cytokine expression (18, 21, 27, 43) and cellular immune response (44). 
Dysregulation of correlations among baseline proinflammatory and regulatory cytokines 
may likely hinder proper immune activation against active viral infection, leading to viral 
persistence. Alternatively, changes in baseline local immunity may potentially serve as a 
stimulus to reactivate viral infection which has stayed latent, resulting in an “incident” 
viral detection. 
In this study, compared to COC users, correlations were significantly weaker among 
immunoregulatory cytokines such as IL-9, IL-15 and IL-17, as well as IL-5, IL-15, IL-17 
in current POC users. The findings suggest differential impacts of estrogen versus 
progesterone on the cervical cytokine milieu. IL-5, IL-9, IL-13 areTh2-type are cytokines 
essential in mediating the pathogenesis of allergy and asthma (45-47), as well as in 
initiating immune responses against helminth parasites (48). These interleukins have been 
shown to associate with an increased HPV viral persistence (49) and high-risk HPV 
prevalence (7). IL-17, which is a pro-inflammatory cytokine, is also associated with 
allergic immune responses in the airway (50) as well as multiple autoimmune diseases 
(51). It was noted in a recent study by Marks et al that HPV infection in older women 
was associated with higher local concentrations of anti-inflammatory and allergy 




eotaxin (29). Reduction in IL-2 and IL-12 levels were suggested in current COC and 
POC users, respectively, in our study. The significant decrease in correlations between 
proinflammatory and immunoregulatory cytokines in hormonal contraceptive users in our 
study further suggests that hormonal contraceptives may impair the basal mucosal 
immunoregulation against HPV by disrupting the overall cytokine balance in older 
women. The relative lack of correlations of allergy-related cytokines in current POC 
users versus COC users indicates possible difference in influences of estrogen and 
progesterone on local allergy-associated immune markers. It is unclear at this point how 
the effects observed may associate with duration of exogenous hormone exposure, and 
what different roles estrogen and progesterone may play in allergy-related immunity in 
the female genital tract. Further studies in those regards are warranted to better 
investigate the biologic roles of hormonal contraceptives in genital immunity in older 
women.   
Our study was limited in power to assess the duration of contraceptive use on cervical 
immunity. It is known that only long-term, not short-term contraceptive use was 
associated with increased risk of HPV prevalence (7). Differences in cumulative or recent 
dosages of exogenous hormone intake may therefore have different impacts on cervical 
immunity. A few cytokines in our study population, including IL-1ra, IL-5, IL-8 and 
eotaxin, yielded >25% of values that were either undetectable or outside the dynamic 
range of the measurement assay and hence were excluded from final analysis and 
interpretation. While our study was short of informative data on those particular 
cytokines, our findings on the correlation patterns were robust with the rest of the 




sensitivity analyses were done with inclusion and exclusion of the imputed cytokine 
values.  
Our study has a number of strengths. Novel techniques were employed for adjusting 
sampling variability in this study. Total protein in cervical secretions was used to 
normalize measured levels of multiple cervical cytokines to produce accurate assessments 
across samples. Data and samples were obtained from a study that specifically examines 
HPV detection in a relatively focused age range across menopausal stages. With detailed 
information collected on demographic factors and the recency of hormonal contraceptive 
use, we were able to assess cervical cytokine profile among women matched on age and 
days of menstrual cycle, accounting for potential confounding due to endogenous 
hormonal fluctuations.  
In summary, our findings suggested that current hormonal contraceptive use diminishes 
the positive correlations among proinflammatory and immunoregulatory cytokines in 
healthy women over the age of 35 years. This effect on baseline cytokine milieu hints at 
potential impairment in eliciting proper cytokine release and immune activation in the 
face of active viral infection.   
Our study was a cross-sectional analysis of cervical cytokine profile. Other factors that 
are subject to hormonal influence, such as immune cells and vaginal flora, may contribute 
to changes of mucosal defense, for which more studies are warranted for better 
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TABLES AND FIGURES 
 









Samples from current* 
hormonal contraceptive 
users 
 n= 105 
(col %) 








Demographic characteristics      
Age  Mean: 42.8. SD: 4.7 Mean: 42.4. SD: 4.7 Mean: 43.1. SD: 4.7 0.31 
  Median: 43. IQR: 7 Median: 42. IQR: 7 Median: 43. IQR: 9  
Race      
Caucasian  139 (66.2) 67 (63.8) 72 (68.6) 0.30 
African American  58 (27.6) 33 (31.4) 25 (23.8)  
Others
 
  13 (6.2) 5 (4.8) 8 (7.6)  
      
      
Marital status      
Married  119 (56.7) 52 (49.5) 67 (63.8) 0.91 
Single  57 (27.1) 28 (35.2) 20 (19.0)  
Divorced/separated/widowed  34 (16.2) 16 (15.2) 18 (17.1)  
      
Parity     0.75 
0 or 1  64 (30.5) 31 (29.5) 33 (31.4)  
2  63 (30.0) 39 (37.1) 44 (22.9)  
>2  83 (39.5) 35 (33.3) 48 (45.7)  
      
Sexual behavioral characteristics      
Lifetime number of sexual 
partners 
    0.63 
1  21 (10.0) 9 (8.6) 12 (11.4)  
2-4  43 (20.5) 20 (19.0) 23 (21.9)  
5-6  38 (18.1) 58 (55.2) 40 (38.1)  




      
Sexual activity in last 6 months      
No sex  30 (14.3) 19 (18.1) 11 (10.5) 0.19 
Have sex but no new sexual 
partner 
 
155 (73.8) 84 (80.0) 81 (77.1) 
 
Have sex with new sexual partner  25 (11.9) 12 (11.4) 13 (12.4)  
      
Ever undergone colposcopy      
No  171 (81.4) 87 (82.9) 84 (80.0) 0.86 
Yes  39 (18.6) 18 (17.1) 21 (20.0)  
      
Time since last abnormal pap smear      
Never had abnormal pap smear  112 (53.3) 48 (45.7) 64 (61.0) 0.54 
<1 year ago  1 (0.5) 0 (0) 0 (0)  
2-5 years ago  45 (21.4) 30 (28.6) 15 (14.3)  
≥6 years ago  52 (24.8) 27 (25.7) 27 (25.7)  
      
*Current users included those with last use ≤ 1 month ago. Non-current controls were selected from those with no use or last use of hormonal 








Protein-adjusted cytokine levels of matched pairs* 
(pg cytokine/mg protein) 
 
Total samples (N=210) 
Current HC users 
(n=105) 
Non-current HC 
controls (n=105)  
Cytokine Mean sd Mean sd Mean sd P** 
IL1b 88.9 137.2 95.8 158.4 81.9 111.8 0.04 
IL2 4.8 12.1 3.0 4.8 6.7 16.3 0.05 
IL4 0.4 0.2 0.3 0.2 0.4 0.3 0.89 
IL6 59.6 82.2 60.2 75.2 59.1 89.0 0.17 
IL7 4.3 4.7 3.4 3.1 5.2 5.8 0.09 
IL9 6.8 5.8 6.6 5.5 7.0 6.1 0.88 
IL10 8.3 7.7 8.1 7.2 8.6 8.2 0.96 
IL12 36.5 30.8 34.9 27.7 38.0 33.7 0.86 
IL13 5.3 4.7 5.0 3.9 5.6 5.3 0.90 
IL15 3.3 3.9 2.9 3.2 3.6 4.4 0.66 
IL17 9.2 9.1 8.7 6.4 9.8 11.2 0.66 
GCSF 590.2 846.1 538.3 532.8 638.1 1057.4 0.50 
GMCSF 214.9 214.2 212.7 207.8 217.2 221.3 0.71 
IFN-γ 30.7 22.2 29.6 18.9 31.9 25.1 0.93 
IP10 1205.1 1801.2 818.4 958.6 1591.7 2302.2 0.03 
MCP1 80.6 127.2 66.6 113.8 94.1 138.1 0.43 
MIP1a 4.0 5.6 4.0 5.2 4.0 6.0 0.45 
MIP1b 68.2 96.2 69.8 75.8 66.6 113.4 0.07 
RANTES 17.8 37.8 18.4 26.5 17.2 46.9 0.06 
TNF-α 6.9 5.2 6.6 4.2 7.2 6.1 0.83 
VEGF 450.0 361.8 448.0 320.6 452.0 401.4 0.30 
FGF 40.9 54.1 38.3 53.1 43.6 55.3 0.60 
PDGF 62.5 56.5 62.3 60.1 62.7 52.9 0.71 
* Samples from current hormonal contraceptive (HC) users and non -current contraceptive users were 
matched by 5-year age categories and closest categories of days of last menstrual period.  




Table 5.3: Distribution of mean cytokine measurements by combined oral contraceptive use and progestin-only contraceptive use 
 
  
Protein-adjusted cytokine levels of matched pairs* 
(pg cytokine/mg protein) 
 
Total samples (N=210) 
Current combined 
oral contraceptive 
users in matched 
pairs (n=41) 
Non-current 
contraceptive users in 










Cytokine Mean sd Mean sd Mean sd P*** Mean sd Mean sd P** 
IL1b 88.9 137.2 86.4 159.1 92.4 124.1 0.86 101.9 174.2 65.3 98.5 0.01 
IL2 4.8 12.1 2.9 3.1 7.4 14.1 0.02 3.2 6.6 6.1 18.7 0.34 
IL4 0.4 0.2 0.3 0.2 0.4 0.4 0.42 0.3 0.2 0.3 0.2 0.20 
IL6 59.6 82.2 57.5 73.1 45.2 64.1 0.46 58.9 66.9 65.2 111.4 0.81 
IL7 4.3 4.7 3.6 2.7 5.9 6.4 0.05 3.0 3.4 4.5 4.2 0.09 
IL9 6.8 5.8 6.5 3.3 7.6 7.4 0.39 5.8 6.0 6.5 4.2 0.50 
IL10 8.3 7.7 9.1 8.8 8.9 10.7 0.91 6.2 4.4 8.4 6.4 0.08 
IL12 36.5 30.8 39.6 31.2 38.7 42.4 0.92 27.1 18.0 36.6 24.9 0.03 
IL13 5.3 4.7 5.6 3.4 5.9 7.0 0.81 3.9 2.8 5.3 3.6 0.048 
IL15 3.3 3.9 3.2 2.6 3.9 5.3 0.50 2.1 2.3 3.6 4.0 0.048 
IL17 9.2 9.1 8.6 4.4 11.8 16.2 0.23 7.3 6.6 8.5 5.6 0.43 
GCSF 590.2 846.1 578.4 483.8 563.3 638.4 0.43 495.2 568.7 679.8 1390.3 0.55 
GMCSF 214.9 214.2 208.8 119.9 233.9 308.2 0.62 169.8 188.9 202.8 124.1 0.35 
IFN-γ 30.7 22.2 31.7 15.5 33.5 30.1 0.74 24.2 14.3 29.8 18.7 0.12 
IP10 1205.1 1801.2 701.5 874.1 1659.7 1832.1 0.002 799.2 809.6 1733.0 2688.4 0.02 
MCP1 80.6 127.2 45.8 63.0 119.5 163.4 0.01 88.4 159.4 85.9 119.3 0.95 
MIP1a 4.0 5.6 3.4 4.2 3.2 5.0 0.87 3.4 3.9 5.1 7.6 0.20 
MIP1b 68.2 96.2 78.3 85.4 43.2 47.3 0.05 53.0 61.5 92.1 159.0 0.24 
RANTES 17.8 37.8 16.8 24.6 10.2 13.4 0.22 19.4 30.9 23.4 68.8 0.66 




VEGF 450.0 361.8 498.7 351.4 459.4 475.3 0.79 362.6 254.7 433.5 324.3 0.22 
FGF 40.9 54.1 38.6 53.0 45.3 64.6 0.61 30.5 39.7 41.6 45.0 0.22 
PDGF 62.5 56.5 68.6 80.5 63.2 51.0 0.72 51.6 40.3 65.5 47.6 0.14 
* Samples from current hormonal contraceptive (HC) users and non-current contraceptive users were matched in 5-year age categories and closest categories of 
days of last menstrual period.  


















Figure 5.4. Heterogeneity of correlation coefficients by different cytokines: current hormonal contraceptive users versus non-















Figure 5.7. Baseline pairwise spearman rank correlations of cytokine measurements in current combined oral contraceptive users 
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SYNOPSIS OF DISSERTATION RESEARCH 
 
The overall objective of this thesis research was to evaluate the association of 
hormonal contraceptive use with human papillomavirus (HPV) detection among pre- 
and perimenopausal women in the U.S. This objective was addressed by the following 3 
study aims. A conceptual model summarizing the hypotheses supported by our study 
findings is shown in figure 6.1 (Figure 6.1). 
 
Aim 1: To determine the association of hormonal contraceptive use with the 
prevalence of HPV DNA detection in pre- and perimenopausal women (N=530) 
Women aged from 35-54 years (mean age was 44.2 years (SD: 5.4 years) were included 
in analyses. Relative to never progestin-only contraceptive (POC) users, more than 5 
years’ use of POCs was associated with increased prevalence of any HPV [adjusted 
prevalence ratio (aPR): 3.16  (95% CI: 1.82-5.48)] and HR-HPV [aPR: 4.26 (95% CI: 
1.60-11.30)]. Current POC use was positively associated with HR-HPV (aPR: 2.44 (0.99-
5.99) and any HPV (aPR: 1.58 (0.94-2.65) with the estimates bordering on statistical 
significance.  No significant association was seen between prevalent HPV infection and 
the recency or duration of oral contraceptive (OC) use in this study cohort.   
Our findings are coherent with those of pooled analyses to date, which revealed neither a 
strong positive or negative association between OC use and HPV prevalent infection (1, 
2). Studies that reported positive associations between HPV infection and OCs or 
combined oral contraceptives (COCs) were mostly conducted in younger women below 




Prevalence of HPV infection is driven by incidence and duration. The difference in 
associations observed in our cohort of older women compared to previous studies 
conducted in younger women may potentially be due to differences in sexual behavioral 
profiles (11), and/or differential effects by types of exogenous female hormones on 
cervical immunity, resulting in differences in proportions of incident vs. transient vs. 
persistent detection at baseline. POC use may have impact on the natural history of HPV 
infection in older women after controlling for sexual behavioral risk factors. A 
longitudinal study was performed (Aim 2) to better define this association and its clinical 
significance.  
 
Aim 2: To estimate the association between hormonal contraceptive use and 
incident HPV DNA detection in pre- and perimenopausal women 
Median follow-up time was 19.1 months with an interquartile range of 7.3 months. 
Relative to never users of POCs, current use of POCs was associated with new HR-HPV 
detection [adjusted odds ratio (aOR): 3.24 (95% CI: 1.37-7.65). No statistically 
significant association was detected between incident HPV detection and current use of 
OCs, nor was there significant association observed between duration of use of overall 
hormonal contraceptives and OCs.  
COC was proposed as a risk factor of HPV prevalence in younger female populations (3-
10) with the association proposed to be driven by COC’s effect on HPV persistence and 
not on acquisition (12). The majority of OCs belongs to the category of COCs (13, 14). 
Our analyses on short-term prospective data revealed that current POC use was 




no significant difference in proportions of persistent prevalent/incident HPV detection at 
6 months was seen in association with any hormonal contraceptive use.  
 
Aim 3: To describe and compare differences in the host cervical cytokine profiles 
among contraceptive users and non-users in pre- and perimenopausal women 
We observed differences in cytokine correlation patterns between current and non-current 
hormonal contraceptive users, as well as between current POC and COC users. In non-
current hormonal contraceptive users, there were significantly more positive correlations 
detected among proinflammatory cytokines, as well as between proinflammatory and 
immunoregulatory cytokines. Compared to COC users, POC users appeared to show 
fewer significant correlations among immunoregulatory cytokines, as well as a 
suggestion of a more predominant Th2-skewed profile as evidenced by significant 
correlations between IL-4, IL-10, and IL-13. The significant decrease in correlations 
between proinflammatory and immunoregulatory cytokines in hormonal contraceptive 
users in our study suggests that hormonal contraceptives may impair the basal mucosal 





Our epidemiologic studies have a number of strengths. Analyses were based on a unique 
study that collected extensive data on the status, types, recency and duration of hormonal 




exposure and its association with HPV infection. In addition, information was collected 
on days of menstrual cycle which reflected endogenous female sex hormonal levels for 
assessment. Furthermore, detailed information was also obtained on sexual behavior and 
other risk factors to evaluate correlates that may confound the associations between HPV 
prevalence and hormonal contraceptive use in older women. 
 
Our study population also had a baseline racial demographic, and sexual behavioral 
characteristics that was generally representative of the U.S. population in this age range 
(11, 15, 16), making our findings relevant to the general population. Participants in the 
study were recruited from women presenting to gynecological clinics who are routinely 
screened for HPV. One of the implications of identifying determinants of HPV detection 
other than sexual behavioral factors, such as hormonal contraceptive use, is to improve 
testing-associated counseling of women who are being screened for cervical cancer. 




Our study has its limitations. Causal inference may be restricted in cross-sectional 
analyses performed for Aims 1 and 3. HPV DNA detection and cytokine levels were 
assessed at only one single time-point at baseline, making inferences challenging. 
Longitudinal association between hormonal contraceptive use and incident HPV 




being planned and performed with 2 years of follow-up data to evaluate the impact of 
hormonal contraceptive use on HPV persistence and clearance. 
 
Similar to other studies on HPV natural history, this thesis research may suffer from left 
truncation bias due to unobserved HPV DNA status prior to study entry, as well as 
interval sampling bias due to unobserved HPV DNA status between study visits (17), 
resulting in cases misclassified as “new” infections, as shown and explained in figure 6.2 
(Figure 6.2). Studies have noted that point prevalence estimates can generally 
underestimate cumulative prevalence by about 20% (18-24). If exogenous hormonal 
exposure, e.g. POCs, causes increase in HPV detection by contributing more to transient 
DNA detection rather than persistent HPV infection, then our study estimates of 
associations are likely to be underestimated due to more “missed” detection related to 
interval censoring among the contraceptive users than in the non-users. On the other hand, 
if exogenous hormonal exposure causes increase in HPV detection by raising risk of 
persistent infection, then the bias impact on the association will likely be less in 
magnitude.   
 
The measurement of exposure to hormonal contraceptives was based on self-report. 
There is a possibility of under-reporting of use as well as differential recall of use related 
to underlying conditions. These would introduce misclassification of exposure which 
would bias the estimates of associations.  Previous studies comparing self-reported 
contraceptive use to clinical records in women aged 20 to 42 years have shown relatively 




current and recent use (25-26). The amount of misclassification introduced by 
discrepancies in self-report of recent use of hormonal contraceptives is thus relatively 
small, which will likely not obscure the directionality of associations obtained from this 
study. 
 
PUBLIC HEALTH IMPLICATIONS 
 
Persistent HPV infection of high-risk HPV (HR-HPV) subtypes is a necessary cause of 
cervical precancer and cancer development. Although prevalence of HPV and HR-HPV 
is observed to be lower in older age groups in the U.S. (27, 28), the rate of cervical cancer 
increases steadily by age after correcting for hysterectomy. While the uncorrected 
cervical cancer rates plateaued at ages 40-44 years, the incidence rate after correcting for 
hysterectomy was shown to increase till the age of 60-69 years (28).  Proper screening for 
cervical cancer and accurate interpretation of screening results is a clinically significant 
issue in women over the age of 35 years.  
 
Women aged 30 to 65 years are currently recommended to be screened with either (i) 
(preferred) cytology and HPV testing every 5 years, or (ii) (acceptable) cytology alone 
every 3 years. (29, 30). The addition of HPV testing to cytology has been shown in 
studies to result in increased detection of CIN3 as well as cervical adenocarcinoma with 
concomitant decrease of precancerous and cancer lesions detected in subsequent 




have been proposed after the U.S. Food and Drug Administration approved the Roche 
Cobas HPV test for primary screening (36).  
 
Application of HPV testing to women older than 30 years but not below also results in 
higher test specificity as HPV prevalence among women 30 years and older is lower than 
among younger women (31). However, interpretation of HPV test results can be 
problematic in women aged >35 years as there is a loss of correlation observed between 
HR-HPV test results and cytologic abnormalities as age increases, likely due to increased 
proportion of ASCUS and reduced prevalence of HR-HPV detected in older women (37).  
 
An optimal screening strategy should be informative on the nature of a positive screening 
result, i.e. whether the result represents a transient HPV detection or an indicator with 
clinical potential to progress to cancerous lesions, so as to avoid unnecessary treatment 
and anxiety.  Current knowledge is limited among older women aged 35 or above in (i) 
determinants of persistent high-risk HPV infection, (ii) biologic roles that risk factors of 
HPV infection may play in the host; (iii) and whether these HPV detections have clinical 
relevance to developing precancerous or cancerous lesions.   
 
Our study findings addressed certain aspects of these knowledge gaps by improving 
current understanding between hormonal contraceptive use and HPV detection among 
older women aged 35-54 years independent of sexual behavior. Older women who are on 
long-term and current use of POCs may carry an increased risk of prevalent HR-HPV and 




related to difference in cervical cytokine milieu observed in current and non-current 
hormonal contraceptive users, as well as between current POC users and current COC 
users.  In contrast to previously published findings which focused mostly in younger 
women, no statistically significant associations were detected in our cohort between HPV 
detection and use of overall hormonal contraceptives and combined oral contraceptives. 
The observed differences hinted at potential differential biologic effects of exogenous 
hormones on local immunity and/or in different age groups that would warrant follow-up 
studies.  
 
Findings obtained from this research will help us to generate hypotheses and future 
studies to further define natural history of HPV infection in older females. Admittedly, 
further studies of a larger scale are needed to address the knowledge gaps in HPV natural 
history to facilitate establishment of an optimal screening strategy in this older age group.  
 
FUTURE DIRECTIONS AND CONCLUSIONS 
 
Future follow-up studies are needed to address the following questions:  
 
Our epidemiologic study findings suggested that long-term and current use of POC’s was 
associated with increased HPV prevalence and incident HPV detection.  
(i) Does incident HPV detection in this cohort represent newly acquired infection, 





Shorter interval follow-up would help to differentiate types of incident HPV detection 
with regard to acquisition or viral reactivation/fluctuation of viral load. HPV genome full 
sequencing can also be incorporated to assess whether the detection reflects a newly 
acquired HPV subtype or a re-emerging detection of a persistent or cleared infection.  
 
(ii) How would HPV type-specific serostatus of vaccinated and unvaccinated older 
women impact on HPV detection with respect to hormonal contraceptive use? 
Studies need to be done with data collected on HPV antibody profile of women in 
different age strata and vaccine status in conjunction with other correlates of HPV 
infection including sexual behavioral risk factors, reproductive characteristics, exogenous 
and endogenous female sex profiles.  
 
(iii) Does increased HPV prevalence detected in this cohort translate to higher risk of 
developing precancerous and cancerous lesions? 
Prospective studies are needed with long-term follow-up to assess the rates of persistence 
and clearance, as well as incident abnormal cytologies and incident invasive cancer. 
These long-term outcomes would need to be interpreted with regard to types, recency and 
duration of hormonal contraceptive use, as well as the types of HPV detection, i.e. 
whether the HPV detection is newly acquired, or is a re-emerged detection of a persistent 
infection or a previously-cleared infection.  
Studies of larger sample size would also be needed to assess long-term outcome with 






Our laboratory study showed that current hormonal contraceptive use at baseline was 
associated with weaker correlations among proinflammatory and immunoregulatory 
cytokines.  
(iv) How wound the difference be interpreted in the context of immune cells and other 
clinical characteristics, and how would that tie to change of HPV status over time? 
Specific cytokine-secreting subpopulations in correlation with cytokine profiles would 
need to be identified, e.g. via multiparameter flow cytometric assays and analyzed with 
multivariate techniques. A longitudinal study would be helpful to study trajectories of 
immune profile over time with change of HPV status among older women.   
 
CONCLUSIONS 
This dissertation showed that long-term and current use of POCs but not OCs may be 
associated with increased risk of prevalent and incident HPV infection independent of 
sexual behavior among pre- and perimenopausal women aged over 35 years with normal 
cervical cytology. Our laboratory study showed differences in cytokine profiles between 
current and non-current hormonal contraceptive users as well as between current POC 
and COC users in HPV-negative women. The study contributes to better understanding of 
the effect of hormonal contraceptive use on HPV detection in women in this age group.  
Further studies are warranted to better define the biologic role(s) of exogenous hormones 
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Figure 6.1. Conceptual model showing hypothesized relationships among HPV detection, progestin-only contraceptive use and 
other correlates of HPV detection in older women. Black solid arrows: Hypothesized pathways consistent with study findings in 





Figure 6.2. Schematic diagram illustrating left truncation and  interval sampling bias in the context of different durations of HPV 
infection. A. Study design with less frequent interval sampling. B. Study design with more frequent interval sampling  
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Figure 6.2. (A and B) Schematic diagram illustrating left truncation and  interval sampling bias in the context of different durations 
of HPV infection.  
Discrepancies in observed HPV status during follow-up by study design 
Hypothesized 
scenarios 
True HPV status over time 
HPV status observed over time via  
study design A 
HPV status observed over time via  
study design B 
Subject #1 
 HPV-positive at study entry 
 
 HPV-positive at t0; infection clears before t1 
 No new detection after t0 
 HPV-positive at t0; infection persists at t1 and clears 
before t2 
 No new detection after t1 
Subject #2 
 HPV-positive (HPV type x1) before t0 
 3 recurrent transient “reactivations” of HPV 
type x1 over time  
 HPV-negative at baseline and during follow-up 
 New detection of HPV type x1 at t1 
 2 recurrent detections of HPV type x1 at t3, t5 
Subject #3 
 HPV-positive (HPV type x2)at t0 
 2 recurrent transient “reactivations” of HPV 
type x2 over time 
 HPV-positive at t0; infection persists at t1 
 1 recurrent transient detection of HPV type x2 over time 
at t3  
 HPV-positive at t0; infection clears before t1 
 2 recurrent transient detections of HPV type x2 over 
time at t2 and t6 
Subject #4 
 HPV-positive (HPV type x3) before t0 
 New detection of HPV type x2, which later in 
time overlaps with recurrence of HPV type x3  
 HPV-negative at baseline  
 New co-detection of HPV type x2 and type x3 at t1 
 No persistence of detection is noted during follow-up 
 HPV-negative at baseline  
 New detection of HPV type x3 at t2 that persists 
through t3 
















Appendix Table 3.1.  
Association between HPV detection and total exposure to any progestin-only contraceptives, with never users of hormonal 
contraceptives as reference group  (N=530) 
 
 
   Positive for any HPV 
n=87 (16.4%) 




 Total N 
N(col %) 
 Any HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
Adjusted  
PRa (95% CI) 
 HR-HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
Adjusted  
PRa (95% CI) 
 
Use of progestin-only contraceptives 
          
 
   Total duration of use 
 
Years 
         
 Never used any hormonal 
contraceptives 
 56 (10.6)  7 (12.5) Ref Ref  4 (7.1) Ref Ref 
 Never used any progestin-
only contraceptives but 
used other hormonal 
contraceptives  
 
384 (72.5)  56 (14.6) 1.17 (0.56-2.43) 1.02 (0.50-2.10)  20 (5.2) 0.73 (0.26-2.06) 0.60 (0.21-1.75) 
 Ever users of progestin-only 
contraceptives 
          
 ≤5  72 (13.6)  15 (20.8) 1.67 (0.73-3.81) 1.19 (0.52-2.71)  5 (6.9) 0.97 (0.27-3.46) 0.84 (0.23-3.03) 
 >5 16 (3.0)  8 (50.0) 4.0 (1.71-9.35) 3.21 (1.37-7.52)  4 (25.0) 3.5 (0.98-12.47) 2.73 (0.73-3.03) 
 Unclear duration  2 (0.4)  1 (50.0) 4.0 (0.85-18.87) 2.09 (0.61-7.23)  1 (50.0) 7.0 (1.31-37.51) 3.56 (0.51-24.79) 
           
a Adjusted for days from last menstrual period, number of lifetime sex partners, acquisition of new sex partner in last 6 months, marital status, time since last abnormal pap smear,  










Appendix Table 3.2.  
Association between HPV detection and recency of any progestin-only hormonal contraceptive use, with never users of hormonal 
contraceptives as reference group (N=530) 
   
 
 Positive for any HPV 
n=87 (16.4%) 




 Total N 
N(col %) 
 Any HPV+ 
n(row %) 
Unadjusted  
PR (95% CI) 
Adjusted  
PRa (95% CI) 
 HR-HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
Adjusted  
PRa (95% CI) 
 
Use of progestin-only contraceptives 
          
           
Last time of use           
 Never used any hormonal 
contraceptives 
 56 (10.6)  7 (12.5) Ref Ref  4 (7.1) Ref Ref 
 Never used any progestin-only 
contraceptives but used other 
hormonal contraceptives 
 
384 (72.5)  56 (14.6) 1.17 (0.56-2.43) 1.02 (0.50-2.09)  20 (5.2) 0.73 (0.26-2.06) 0.60 (0.20-1.76) 
 Current user   47 (8.9)  13 (27.7) 2.21 (0.96-5.09) 1.60 (0.70-3.67)  6 (12.8) 1.79 (0.54-6.00) 1.57 (0.43-5.70) 
 Past user  43 (8.1)  11 (25.6) 2.05 (0.87-4.84) 1.54 (0.66-3.60)  4 (9.3) 1.30 (0.34-4.92) 1.05 (0.30-3.63) 
           
a Adjusted for days from last menstrual period, number of lifetime sex partners, acquisition of new sex partner in last 6 months, marital status, time since last abnormal pap smear,  history 





Appendix Table 3.3. 
Association between HPV detection and total exposure to any oral contraceptives, with never users of hormonal contraceptives 
as reference group  (N=530) 
 
 
   Positive for any HPV 
n=87 (16.4%) 




 Total N 
N(col %) 
 Any HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
Adjusted  
PRa (95% CI) 
 HR-HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
Adjusted  
PRa (95% CI) 
 
Use of oral contraceptives 
          
 
   Total duration of use 
 
Years 
         
 Never used any hormonal 
contraceptives 
 56 (10.6)  7 (12.5) Ref Ref  4 (7.1) Ref Ref 
 Never used any oral 




39 (7.4)  14 (35.9) 2.87 (1.28-6.46) 1.91 (0.86-4.21)  6 (15.4) 2.15 (0.65-7.14) 1.52 (0.47-4.89) 
 Ever users of oral 
contraceptives 
          
 ≤5  211 (39.8)  32 (15.2) 1.21 (0.57-2.60) 1.01 (0.48-2.14)  14 (6.6) 0.93 (0.32-2.71) 0.82 (0.28-2.41) 
 >5 197 (37.2)  30 (15.2) 1.22 (0.57-2.63) 1.12 (0.53-2.39)  7 (3.6) 0.50 (0.15-1.64) 0.37 (0.11-1.19) 
 Unclear duration  27 (5.1)  4 (14.8) 1.19 (0.38-3.71) 0.89 (0.32-2.52)  3 (11.1) 1.56 (0.37-6.48) 1.08 (0.26-4.51) 
           
a Adjusted for days from last menstrual period, number of lifetime sex partners, acquisition of new sex partner in last 6 months, marital status, time since last abnormal pap smear,  









Appendix Table 3.4. 
Association between HPV detection and recency of any oral contraceptive use, with never users of hormonal contraceptives as 
reference group (N=530) 
   
 
 Positive for any HPV 
n=87 (16.4%) 




 Total N 
N(col %) 
 Any HPV+ 
n(row %) 
Unadjusted  
PR (95% CI) 
Adjusted  
PRa (95% CI) 
 HR-HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
Adjusted  
PRa (95% CI) 
 
Use of oral contraceptives 
          
           
Last time of use           
 Never used any hormonal 
contraceptives 
 56 (10.6)  7 (12.5) Ref Ref  4 (7.1) 4 (7.1) Ref 
 Never used any oral 
contraceptives but used other 
hormonal contraceptives 
 
39 (7.4)  14 (35.9) 2.87 (1.28-6.46) 1.91 (0.86-4.21)  20 (5.2) 6 (15.4) 1.55 (0.49-4.i97) 
 Current user   63 (11.9)  10 (15.9) 1.27 (0.52-3.11) 0.97 (0.40-2.36)  6 (12.8) 4 (6.4) 0.56 (0.13-2.40) 
 Past user  372 (70.2)  56 (15.1) 1.20 (0.58-2.51) 1.06 (0.52-2.17)  4 (9.3) 20 (5.40 0.67 (0.23-1.94) 
           
a Adjusted for days from last menstrual period, number of lifetime sex partners, acquisition of new sex partner in last 6 months, marital status, time since last abnormal pap smear,  history 









Appendix Table 3.5.  
Association between HPV detection and total exposure to combined oral contraceptive use (N=530) 
 
 
   Positive for any HPV 
n=87 (16.4%) 




 Total N 
N(col %) 
 Any HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
Adjusted  
PRa (95% CI) 
 HR-HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
Adjusted  
PRa (95% CI) 
 
Use of combined oral contraceptives 
          
 
   Total duration of use 
 
Years 
         
 Never used any hormonal 
contraceptives 
 56 (10.6)  7 (12.5) Ref Ref  4 (7.1) Ref Ref 
 Never used any combined 




















 Ever users of combined oral 
contraceptives 
          
 ≤5  101 (19.1)  11 (10.9) 0.87 (0.36-2.12) 0.74 (0.31-1.78)  5 (5.0) 0.69 (0.19-2.48) 0.62 (0.17-2.28) 
 >5 86 (16.2)  13 (15.1) 1.21 (0.51-2.85) 1.05 (0.45-2.45)  3 (3.5) 0.49 (0.11-2.10) 0.35 (0.08-1.51) 
 Reported use of “pills” 
without specifying 
medication brand names 
 253 (47.7)  43 (17.0) 1.36 (0.65-2.86) 1.20 (0.58-2.48)  17 (6.7) 0.94 (0.33-2.70) 0.77 (0.26-2.24) 
           
a Adjusted for days from last menstrual period, number of lifetime sex partners, acquisition of new sex partner in last 6 months, marital status, time since last abnormal pap smear,  







Appendix Table 3.6.  
Association between HPV detection and recency of combined oral contraceptive use (N=530) 
   
 
 Positive for any HPV 
n=87 (16.4%) 




 Total N 
N(col %) 
 Any HPV+ 
n(row %) 
Unadjusted  
PR (95% CI) 
Adjusted  
PRa (95% CI) 
 HR-HPV+  
n(row %) 
Unadjusted  
PR (95% CI) 
Adjusted  
PRa (95% CI) 
 
Use of combined oral contraceptives 
          
           
Last time of use           
 Never used any hormonal 
contraceptives 
 56 (10.6)  7 (12.5) Ref Ref  4 (7.1) Ref Ref 
 Never used any combined oral 
contraceptives but used other 
hormonal contraceptives 
  













 Current user   46 (8.7)  6 (13.0) 1.04 (0.38-2.89) 0.90 (0.33-2.46)  3 (6.5) 0.91 (0.21-3.88) 0.76 (0.16-3.51) 
 ≤5 years ago   32 (6.0)  2 (6.3) 0.50 (0.11-2.27) 0.33 (0.07-1.54)  1 (3.1) 0.44 (0.05-3.76) 0.26 (0.03-2.45) 
 6-10 years ago  29 (5.5)  6 (20.7) 1.66 (0.61-4.48) 1.46 (0.54-3.95)  1 (3.5) 0.48 (0.06-4.13) 0.42 (0.07-2.48) 
 >10 years ago  81 (15.3)  10 (12.1) 0.96 (0.39-2.38) 0.93 (0.38-2.25)  3 (3.6) 0.51 (0.12-2.18) 0.46 (0.10-2.04) 
 Use of “the pills” without 
specifying medication brand 
names 
 
253 (47.7)  43 (17.1) 1.37 (0.65-2.89) 1.20 (0.58-2.50)  17 (6.8) 0.95 (0.33-2.71) 0.78 (0.27-2.26) 
a Adjusted for days from last menstrual period, number of lifetime sex partners, acquisition of new sex partner in last 6 months, marital status, time since last abnormal pap smear,  history of 








Appendix Table 4.1. Baseline characteristics of study population who had at least 6-month follow-up at the time of analysis 
 
Characteristics at baseline 
 
Total at baseline 
N=530 
(col %)a 
Population with at least 6-






 Population not yet having 






Baseline status of any HPV       0.12 
Negative  443 (83.6) 326 (85.1)   117 (79.6)  
Positive  87 (16.4) 57 (14.9)   30 (20.4)  
        
Baseline status of any HR-HPV       0.01 
Negative  496 (93.6) 365 (95.3)   1131 (89.1)  
Positive  34 (6.4) 18 (4.7)   16 (10.9)  
        
Demographic characteristics        
Age (years)        
35-39  126 (23.8) 98 (25.6)   28 (19.1) 0.004 
40-44  148 (27.9) 103 (26.9)   45 (30.6)  
45-49  157 (29.6) 119 (31.1)   38 (25.9)  
≥50  99 (18.7) 63 (17.5)   36 (24.5)  
        
Race       0.58 
Caucasian  392 (74.0) 288 (75.2)   104 (70.8)  
African American  99 (18.7) 68 (17.8)   31 (21.1)  
Others b  39 (7.4) 27 (7.1)   12 (8.2)  
        
Education status       0.03 
High school  84 (15.9) 56 (14.6)   28 (19.1)  
Post-high school  122 (23.0) 78 (20.4)   44 (29.9)  
College graduate  166 (31.3) 129 (33.7)   37 (25.2)  
Post-college  158 (29.8) 120 (31.3)   38 (25.9)  
        
Marital status       0.32 
Married  339 (64.0) 252 (65.8)   87 (59.2)  
Single  107 (20.2) 75 (19.6)   32 (21.8)  
Divorced/separated/widowed  84 (15.9) 56 (14.6)   28 (19.1)  
        
Current smoker       0.03 




Yes  55 (10.4) 33 (8.6)   22 (15.0)  
        
Parity       0.58 
0 or 1  170 (32.1) 124 (32.5)   46 (31.3)  
2  124 (23.4) 85 (22.3)   39 (26.5)  
>2  235 (44.4) 173 (45.3)   62 (42.2)  
        
Sexual behavioral characteristics        
Lifetime number of sexual partners       0.05 
≤2  59 (11.1) 51 (13.3)   8 (5.4)  
3-4  134 (25.3) 99 (25.9)   35 (23.8)  
5-6  215 (40.6) 150 (39.2)   65 (44.2)  
>10  122 (23.0) 83 (21.7)   39 (26.5)  
        
Sexual activity in last 6 months       0.46 
No sex  86 (16.2) 58 (15.1)   28 (19.1)  
Have sex but no new sexual partner  429 (80.9) 313 (81.7)   116 (78.9)  
Have sex with new sexual partner  15 (2.8) 12 (3.1)   3 (2.0)  
        
Last menstrual period (days)       0.001 
1-14  227 (42.8) 178 (46.5)   49 (33.3)  
15-28  174 (32.8) 123 (32.1)   51 (34.7)  
28-40  34 (6.4) 28 (7.3)   6 (4.1)  
40-365  95 (17.9) 54 (14.1)   41 (27.9)  
        
Ever undergone colposcopy       0.21 
No  425 (80.2) 302 (78.9)   123 (83.7)  
Yes  105 (19.8) 81 (21.2)   24 (16.3)  
        
Ever undergone treatment for abnormal pap 
smear 
      0.57 
No  430 (81.1) 33 (81.3)   117 (79.6)  
Yes  100 (18.9) 70 (18.3)   30 (20.4)  
        
Time since last abnormal pap smear       0.80 
Never had abnormal pap smear  289 (54.5) 210 (54.8)   79 (53.7)  
<1 year ago  11 (2.1) 9 (2.4)   2 (1.4)  
2-5 years ago  59 (11.1) 44 (11.5)   15 (10.2)  
≥6 years ago  171 (32.3) 120 (31.3)   51 (34.7)  
        
Diagnosed with other sexually transmitted 
infections  in the past 6 months c 




No  517 (94.5) 372 (97.1)   145 (98.6)  
Yes  13 (5.5) 11 (2.9)   2 (1.4)  
 
Hormonal contraceptives: 






      
Duration of use by recency Years      0.78 
 Never used any hormonal 
contraceptives 
 56 (10.6) 42 (11.0)   14 (9.5)  
Current  ≤5 82 (15.5) 58 (15.1)   24 (16.3)  
 >5  30 (5.9) 24 (6.3)   7 (4.8)  
Former ≤5 179 (33.8) 134 (35.0)   45 (30.6)  
 >5  161 (30.4) 111 (29.0)   50 (34.0)  
Unclear duration  22 (4.0) 14 (3.7)   7 (4.8)  
        
Time since last use       0.78 
 Never user   56 (10.6) 42 (11.0)   14 (9.5)  
Current user   112 (21.1) 81 (21.2)   31 (21.1)  
Last use ≤ 5 years ago  74 (14.0) 57 (14.9)   17 (11.6)  
Last use  6-10 years ago  63 (11.9) 46 (12.0)   17 (11.6)  
Last use >10 years ago  225 (42.5) 157 (41.0)   68 (46.3)  
        
 
Use of any progestin-only contraceptives 
 









 Never used any progestin-only 
contraceptives 
 440 (83.0) 319 (83.3)   121 (82.3)  
 ≤5 72 (13.6) 51 (13.3)   21 (14.3)  
 >5  16 (2.8) 12 (3.1)   4 (2.7)  
Unclear  2 (0.4) 1 (0.3)   1 (0.7)  
        
Time since last use        0.11 
 Never used any progestin-only 
contraceptives 
 440 (83.0) 319 (83.3)   121 (82.3)  
Current user   47 (8.9) 29 (7.6)   18 (12.2)  
Past user   43 (8.1) 35 (9.1)   8 (5.4)  
        
 
Use of oral contraceptives  
 













 Never used any oral contraceptives  95 (17.9) 69 (18.0)   26 (17.7)  
 ≤5 211 (39.8) 153 (40.0)   58 (39.5)  
 >5  197 (37.2) 142 (37.1)   55 (37.4)  
Unclear duration  27 (5.1) 19 (5.0)   8 (5.44)  
        
Time since last use        0.39 
 Never used any oral 
contraceptives 
 95 (17.9) 69 (18.0)   26 (17.7)  
Current user   63 (11.9) 50 (13.1)   13 (8.8)  
Past user  372 (70.2) 264 (68.9)   108 (73.5)  
        
a. Percentages or numbers in categories may not add up to 100% or the total number due to missing data.  
b. Other categories include American Indian (n=2), Pacific Islander (n=2), Asian (n=16), unidentified (n=9).  




Appendix  Table 4.2. Baseline characteristics of visits with persistent HPV detection during follow-up (Total number of positive 
HPV detections that had 6 month-follow-up: 179) 
 
Characteristics at baseline 
 Total number of 
positive HPV detections 





Any HPV detection with 
persistence at  









Demographic characteristics      
Age at baseline  (years)    0.38  
35-39  61 (34.1) 42 (68.9)   
40-44  31 (17.3) 18 (58.1)   
45-49  59 (33.0) 36 (61.0)   
≥50  28 (15.6) 14 (51.9)   
      
Race      
Caucasian  137 (76.5) 85 (62.0) 0.91  
African American  31 917.3) 18 (58.1)   
Others c  11 (6.2) 7 (63.60   
      
Marital status    0.83  
Married  68 (38.0) 40 (58.8)   
Single  47 (26.3) 29 (61.7)   
Divorced/separated/widowed  64 (35.8) 41 (64.1)   
      
Smoker in the past 6 months    0.40  
No  167 (93.3) 104 (62.3)   
Yes  12 (6.7) 6 (50.0)   
      
Parity at baseline    0.63  
0 or 1  95 (53.1) 59 (62.1)   
2  28 (15.6) 19 (67.9)   
>2  56 (31.3) 32 (57.1)   
      
Sexual behavioral characteristics      
Lifetime number of sexual partners    0.95  
<5  32 (17.9) 19 (59.4)   
5-10  96 (53.60 60 (62.5)   




      
Sexual activity in last 6 months    0.81  
No sex  20 (11.2) 11 (55.0)   
Have sex but no new sexual partner  137 (76.5) 85 (62.0)   
Have sex with new sexual partner  22 (12.3) 14 (63.6)   
      
Last menstrual period (days)    0.29  
1-14  57 (31.8) 30 (52.6)   
15-28  76 (42.5) 48 (63.2)   
28-40  10 (5.6) 6 (60.0)   
40-365  36 (20.1) 26 (72.2)   
      
Ever undergone colposcopy    0.60  
No  131 (73.2) 82 (62.6)   
Yes  48 (26.8) 28 (58.3)   
      
Time since last abnormal pap smear at baseline    0.16  
Never had abnormal pap smear  92 (51.4) 63 (68.5)   
<1 year ago  10 (5.6) 4 (40.0)   
2-5 years ago  23 (12.9) 14 (60.9)   
≥6 years ago  54 (30.2) 29 (53.7)   
      
Diagnosed with other sexually transmitted infections  in the 
past 6 months* 
   0.08  
No  170 (95.0) 102 (60.0)   
Yes 
 
 9 (5.0) 8 (88.9)   







 Appendix Table 4.3. Baseline hormonal contraceptive use and persistent HPV detection at 6 months during follow-up (Total 
number of positive HPV detections that had 6 month-follow-up: 179) 
 
Characteristics at baseline 
 Total number of positive 





Any HPV detection with 
persistence at  
6 months  
 
N=110(61.5%) 


















Duration of use by recency Years   0.32  
 Never used any hormonal contraceptives  19 (10.6) 12 (63.2)   
 ≤5 101 (56.4) 66 (65.4)   
 >5  54 (30.2) 28 (51.9)   
Unclear duration  5 (2.8) 4 (80.0)   
      
Time since last use    0.65  
 Never user   19 (10.6) 12 (63.2)   
Current user   50 (27.9) 28 (56.0)   
Past user  110 (61.5) 70 (63.6)   
      
      
      
 
Use of any progestin-only contraceptives 
 










 Never used any progestin-only 
contraceptives 
 122 (68.2) 79 (64.8)   
Ever users      
 ≤5 45 (25.1) 24 (53.3)   
 >5  9 (5.0) 5 (55.6)   
Unclear  3 (1.7) 2 (66.7)   
      
      
Time since last use     0.13  
 Never used any progestin-only 
contraceptives 




Current user   28 (15.6) 18 (64.3)   
Past users  29 (16.2) 13 (44.8)   
      
 
Use of any oral contraceptives 
 









 Never used any oral contraceptives  45 (25.1) 26 (57.8)   
Ever users       
 ≤5 61 (34.1) 42 (68.9)   
 >5  65 (36.3) 35 (53.9)   
Unclear duration  8 (4.5) 7 (87..5)   
      
Time since last use     0.26  
 Never used any oral contraceptives  45 (25.1) 26 (57.8)   
Current user   21 (11.7) 10 (47.6)   
Past user   113 (63.1) 74 (65.5)   













cytokine levels  
(pg cytokine/mg protein) Outside detection range (%) 
 
 
Total samples (N=210) Total  
samples 
(n=210) 





Cytokine Median IQR p* 
IL1b 38.75 89.53 10.4 8.9 11.9 0.49 
IL1ra 6724.67 11334.13 81.7 82.2 81.2 0.86 
IL2 1.90 2.10 2.5 4 1 0.17 
IL4 0.31 0.22 0 0 0 na 
IL5 0.65 0.74 59.9 66.3 53.5 0.06 
IL6 23.84 70.75 0.5 0 1 0.32 
IL7 2.89 3.01 2 3 1 0.31 
IL8 217.61 227.41 54.5 56.4 52.5 0.57 
IL9 5.13 5.55 1 2 0 0.16 
IL10 6.33 6.99 0 0 0 na 
IL12 28.74 32.95 0 0 0 na 
IL13 4.01 3.85 2 3 1 0.31 
IL15 2.02 3.72 16.8 18.1 14.9 0.45 
IL17 7.15 6.64 0 0 0 na 
EOTAXIN 5.61 11.58 33.7 31.7 35.6 0.55 
GCSF 398.70 636.72 21.8 24.8 18.8 0.89 
GMCSF 161.58 197.49 0.5 1 0 0.32 
IFN-γ 25.28 17.99 0 0 0 na 
IP10 517.17 1191.11 3 3 3 1 
MCP1 37.72 76.66 4 5.9 2 0.15 
MIP1a 1.97 2.80 1.5 1 2 0.56 
MIP1b 39.81 67.28 6.9 6.9 6.9 1 
RANTES 7.33 15.26 5.5 5 5.9 0.76 
TNF-α 5.26 5.37 0 0 0 na 
VEGF 348.32 427.62 3.5 2.0 5.0 0.25 
FGF 20.06 32.36 0.5 0 1 0.32 









Appendix Table 5.2. Current hormonal contraceptive use by type among subjects 
included for cervical cytokine measurement 
 Total number of cases included 
for study (N=105) n (%) 
Use of any hormonal contraceptive 105 (100) 
Combined oral contraceptive (COC) 41 (39.0) 
 “Birth control pills”/”pills”  13 (12.4) 
Progestin-only contraceptives   
Mirena 23 (21.9) 
Oral pills 21 (20.0) 
DMPA 6 (5.7) 
Nuva ring  3 (2.9) 
Current use of dermal patch 1 (1.0) 
Overlapping use of COC and mirena  1 (1.0) 
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mutual associations between the incidence of HPV infection and other sexually 
transmitted infections after controlling for sexual behavior? 19
th
 Conference of the 
International Society for STD Research, Québec City, Canada. Oral presentation. (July 
11, 2011) 
 
Soong TR, Gravitt PE, Gupta SB, Liaw K, Kim K, Tadesse A, Phongnarisorn C, 
Wootipoom V, Yuenyao P, Vipupinyo C, Sriplienchan S, Celentano DD. Genital 
chlamydia and gonorrhea are independent predictors of HPV prevalence. North 
American Congress of Epidemiology, Montreal, Canada. Poster presentation. (June 21, 
2011) 
 
Soong TR, Jung, JJ, Rothman RE, Gabor KD, Burah A, Shahan J, Hsieh Y-H. 
Inadequate HIV care is associated with increased emergency department utilization and 
hospitalizations: A prospective study in HIV-positive patients. Society for Academic 
Emergency Medicine 2010 Annual Meeting, Phoenix, AZ. Poster presentation. (June 3, 
2010) 
 
Soong TR, Pathak AP, Asano H, Fox-Talbot K, Baldwin WM 3
rd
. Lymphatic injury 
and regeneration patterns are associated with alloimmune responses in cardiac 
allografts.  American Transplant Congress, Toronto, Canada. Poster presentation. 





Soong TR, Barouch LA, Champion HC, Wigley FM, Halushka MK. New clinical and 
ultrastructural findings in hydroxychloroquine-induced cardiomyopathy – a report of 
two cases. American College of Physicians 25th Annual 
Maryland Associates Meeting, Baltimore, MD. Poster presentation (May 17, 2007) 
(Poster was also selected for presentation at national meeting of Internal Medicine 





05/2015 Course Instructor 
Microbiology Clinical Pathological Correlation Conferences of 
Immunology, Infectious Disease, and Pathology (IMP) Course 







Short Course Instructor 
Practical Statistics for Pathologists: Case-Based Instruction with 
Methods 
United States and Canadian Academy of Pathology (USCAP) 
2014 Annual Meeting, San Diego CA (03/26/2015) 
United States and Canadian Academy of Pathology (USCAP) 
2015 Annual Meeting, Boston MA (03/05/2014) 
 
08/2009  –  03/2012 Teaching Assistant  
PH 340.751-752 (Epidemiologic Methods) 
PH 140.621-623 (Statistical Methods in Public Health) 
Johns Hopkins Bloomberg School of Public Health, Baltimore 
MD  
 
12/2008  –  01/2009 Student Instructor, gross anatomy sessions for first-year 
medical students,  
Johns Hopkins University School of Medicine, Baltimore MD  
 
06/2004  –  08/2004 Tutor, MCAT preparatory courses  
Princeton Review, Baltimore MD  
 
09/2001  –  05/2003 Tutor for undergraduate physics courses, Student Learning 
Center,  
University of California, Berkeley CA 
 
 
MEMBERSHIP IN PROFESSIONAL SOCIETY 
 






05/2012  –  present American Medical Association  
 
 
MEMBERSHIP IN HONOR SOCIETIES 
 
05/2009  –  present Delta Omega Honorary Society in Public Health, Alpha 
Chapter 
 
05/2003  –  present Phi Beta Kappa Society 
 
 
